



New triazole-based hybrids as neurotropic agents†

 Cite this: *RSC Adv.*, 2024, **14**, 32922

 Samvel N. Sirakanyan,^a Domenico Spinelli,^b Athina Geronikaki,^{*c} Elmira K. Hakobyan,^{*a} Anti Petrou,^c Victor G. Kartsev,^d Hasmik A. Yegoryan,^a Ervand G. Paronikyan,^a Luca Zuppiroli,^e Hasmik V. Jughetsyan,^a Ruzanna G. Paronikyan,^a Tatevik A. Arakelyan^a and Anush A. Hovakimyan^a

Herein, we describe the synthesis of new hybrids linked to 1,2,3- and 1,2,4-triazole units. Hybrids connected to a 1,2,3-triazole ring were synthesized using the well-known click reaction. The synthesis of the 1,2,4-triazole-based hybrids was carried out using 2-[(4-cyano-1-methyl(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl)oxy]acetohydrazides as starting compounds. The compounds were evaluated for their anticonvulsive activity *via* antagonism towards pentylentetrazole (PTZ) – and thiosemicarbazide (TSC)-induced convulsion and maximal electroshock-induced seizure (MES). Furthermore, the most active compounds were studied for their locomotory and anxiolytic activity *via* the “open field” and elevated plus maze (EPM) assays. Finally, their antidepressant activity was studied *via* the “forced swim” method. All the hybrids displayed pentylentetrazole antagonism, ranging from 40% to 80%, while in the TSC model, the most active compounds increased latency of thiosemicarbazide seizures to 1.9–4.65 times compared to that of the control. Some of the tested compounds exhibited a pronounced anxiolytic and antidepressant effect. Docking study demonstrated complete agreement with experimental pharmacological data. It was revealed that the most active compounds have a pyrano[3,4-*c*]pyridine ring in their structure.

 Received 23rd August 2024
 Accepted 5th October 2024

DOI: 10.1039/d4ra06121g

rsc.li/rsc-advances

1. Introduction

The wide prevalence of mental disorders, including epilepsy, one of the most severe diseases of the central nervous system, along with the lack of efficacy and side effects of existing anti-convulsants, makes the search and study of the mechanisms of action of new anticonvulsants imperative.^{1,2} Epilepsy is the most common neurological disease, with a prevalence ranging from 0.5% to 1% in developed countries.³ Convulsions arise as a result of an imbalance between the excitatory and inhibitory systems of the central nervous system.

The main component in the complex treatment of epilepsy is pharmacotherapy—the use of anticonvulsants or antiepileptic drugs. Today, about 30 antiepileptic drugs are used in

medicine. Such a number of medicines for the treatment of one disease is necessary because different medicines have different mechanisms of action. Each drug is most effective for only a certain form of epilepsy, which differs in the individual mechanism for the development of an attack in the brain. In recent years, in the treatment of epilepsy using antiepileptic drugs, mainly second-generation drugs, the tendency has been to optimize the treatment, aimed at the use of anticonvulsants with extended combined neurotropic properties.⁴

Heterocyclic compounds have attracted interest from the scientific community as a pool for development of new biologically active compounds. Thus, numerous publications refer to the neurotropic activity of pyridine derivatives.^{5–9} Another interesting scaffold is triazole derivatives, which besides their known antimicrobial activity,^{10–12} have been reported to possess antiepileptic/antidepressant activity.^{13–15}

Recently, we synthesized some hybrid compounds^{16,17} *via* the click reaction^{18–20} and studied their neurotropic activity.¹⁷ The obtained results demonstrated that some compounds can be effective in various types of human epilepsy associated with mental disorders.¹⁷ It should be noted that starting compounds used for the synthesis of target hybrids are derivatives of biologically active compounds. In particular, compounds with a terminal triple bond were synthesized starting from 3(6)-hydroxypyridines **1**, among which a compound with both strong antiplatelet and vasodilatory potential and with an IC₅₀ two-times lower than that of clinically used acetylsalicylic acid was

^aScientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, 0014, Armenia. E-mail: shnr@mail.ru

^bDipartimento di Chimica G. Ciamician, Alma Mater Studiorum-Università di Bologna, Via F. Selmi 2, Bologna 40126, Italy. E-mail: domenico.spinelli@unibo.it

^cAristotle University of Thessaloniki, School of Pharmacy, Thessaloniki-54124, Greece. E-mail: geronik@pharm.auth.gr

^dInterBioScreen, Moscow 119019, Russia. E-mail: vkartsev@ibscreen.chg.ru

^eDepartment of Industrial Chemistry ‘Toso Montanari’, Alma Mater Studiorum-Università di Bologna, Viale del Risorgimento 4, Bologna, 40136, Italy. E-mail: luca.zuppiroli@unibo.it

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4ra06121g>






Fig. 1 Alkaloids: gentianine I, gentianidine II and drugs bearing piperazine core III and IV.

revealed.²¹ The preparation of compounds bearing azido group was performed using piperazinopyridines, which are known for their pronounced neurotropic^{22,23} and antimicrobial²⁴ activities. Alternatively, the target hybrids were linked with 1,2,3- and 1,2,4-triazole rings, and their derivatives exhibited a wide range of bioactive properties.^{25–27}

The structure of our initial compound bicyclic pyridine is very similar to that of the alkaloids gentianine I and gentianidine II,²⁸ which are endowed with a wide range of bioactivities and used in medicine (Fig. 1). Alternatively, the piperazine core is included in various synthetic drugs such as befuraline III and ziprasidone IV, which are drugs approved by the FDA.^{29,30} Befuraline III (DIV-154) is a psychoactive drug, which has stimulant and antidepressant effects. Ziprasidone IV is an atypical antipsychotic drug used to treat schizophrenia, bipolar mania, and acute agitation in schizophrenic patients (Fig. 1).

Considering all the above-mentioned factors and in continuation of our studies on the synthesis of potentially biologically active hybrid compounds, herein we report the synthesis of new representatives of these compounds (besides compounds 6a, j and m,¹⁶) and studied their neurotropic properties.


2. Results and discussion

2.1. Chemistry


The azido derivatives were synthesized starting from 3(6)-piperazinopyridines 1a–g.^{16,17} Compounds 1 were acylated with chloroacetyl chloride in benzene with the formation of 4-(chloroacetyl)piperazinopyridines 2a–g, respectively.^{16,17} Then, the obtained chlorides 2 were reacted with sodium azide in acetone and the corresponding 4-(azidoacetyl)piperazinopyridines 3a–g,^{16,17} were synthesized, respectively (Scheme 1).

The terminal alkynes were synthesized starting from the 3(6)-hydroxy derivatives of cyclopenta[*c*]pyridine 4a,³¹ 5,6,7,8-tetrahydroisoquinolines 4b–f,³¹ and pyrano[3,4-*c*]pyridines 4g–i.³² As shown in our previous paper,¹⁷ the alkylation of compounds 1 with propargyl bromide in basic medium proceeds almost regioselectively with the formation of *O*-alkylated derivatives in high yields and the traces of *N*-alkylated compounds were removed by recrystallization from ethanol (Scheme 2). Moreover, in our previous paper, in one instance we succeeded in separating the *O*- and *N*-alkylated compounds, also confirming their structure by X-ray data.¹⁷

Finally, the target hybrids 6a–q (resynthesis was carried out for compounds 6a, j and m,¹⁶) were synthesized in high yields




Scheme 1 Synthesis of compounds 2a–g and 3a–g. (a) ClCH₂COCl, C₆H₆, Et₃N, 35 °C, 6 h; (b) NaN₃, MeCOMe, reflux, 15 h. 1–3. a, b: X = CH₂, *n* = 0, R = H, a: R¹ = *n*-Pr; b: R¹ = *i*-Bu; c–e: X = CH₂, *n* = 1, R = H, c: R¹ = Me; d: R¹ = *i*-Pr; e: R¹ = 2-furyl; f, g: X = O, *n* = 1, R = Me, f: R¹ = Me; g: R¹ = Et.



Scheme 2 Synthesis of compounds 5a–i. 4, 5: a: X = CH₂, *n* = 0, R = H, R¹ = *i*-Pr; b: X = CH₂, *n* = 1, R = H; R¹ = Me; c: R¹ = Et; d: R¹ = *i*-Pr; e: R¹ = Ph; f: R¹ = 2-furyl; g: X = O, *n* = 1, R = Me; R¹ = *i*-Pr; h: R¹ = *p*-MeOC₆H₄; i: R¹ = 2-furyl.

via the click reaction^{16–20} between 4-(azidoacetyl)piperazinopyridines 3 and *O*-alkylated compounds 5 (Y = 71–87%; Scheme 3, Table 1). The structure of compounds 6 was defined spectroscopically and by elemental analysis. In the IR spectra of compounds 6a–q, the absorption bands of the azido group (2103–2111 cm⁻¹) and triple bond (2121–2131 and 3268–3276 cm⁻¹) disappeared, with the appearance of the singlet signal of the triazole ring at 7.92–8.02 ppm in the ¹H NMR spectra. The MS spectra correspond to the expected structure of the compounds.

From both chemical and biological point of views, it was also interesting to synthesize hybrid compounds based on 1,2,4-triazole derivatives. For this purpose, the previously synthesized 2-[[4-cyano-1-methyl(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy]-acetohydrazides 7a and b,³¹ and 2-[[5-cyano-8-(2-furyl)-3,3-




Scheme 3 Synthesis of 1,4-disubstituted 1,2,3-triazoles 6a–q.




Table 1 Target hybrids linked with a 1,2,3-triazole unit (6a–q)

No.	Hybrids	No.	Hybrids
6a		6j	
6b		6k	
6c		6l	
6d		6m	
6e		6n	
6f		6o	
6g		6p	
6h		6q	
6i			





Scheme 4 Synthesis of compounds 9a–c. 7–9. a: X = CH₂, R = H, R¹ = Me; b: X = CH₂, R = H, R¹ = 2-furyl; c: X = O, R = Me, R¹ = 2-furyl.



Scheme 5 Synthesis of 3,5-disubstituted 1,2,4-triazoles 10a–g.

dimethyl-3,4-dihydro-1*H*-pyrano[3,4-*c*]pyridin-6-yl]oxy} aceto-hydrazide **7c**,³² were used. Thus, compounds **7a–c** upon reaction with phenylisothio-cyanate in absolute ethanol resulting the corresponding thioureido derivatives **8a–c**, which were further cyclized into the corresponding 1,2,4-triazoles **9a–c** in high yields, respectively (Scheme 4).

Finally, alkylation of the obtained 1,2,4-triazoles **9a–c** using compounds **2** as alkylating agents led to the designed 3,5-disubstituted 1,2,4-triazoles (Scheme 5 and Table 2).

In the ¹H NMR spectra of the obtained 3,5-disubstituted 1,2,4-triazoles **10a–g**, the singlet signals of the OCH₂ and SCH₂ groups appeared at 5.36–5.60 ppm and 4.30–4.33 ppm, respectively.

2.2. Biological evaluation

Twenty-four newly synthesized heterocyclic compounds, **6a–q** and **10a–g**, were evaluated for their neurotropic activities and side effects.

The preclinical development of new chemical agents for the treatment of epilepsy is routinely based on the use of animal models that imitate the given type of human seizures.

For the evaluation of the anticonvulsant activity of the hybrids, they were assessed based on their antagonism to pentylenetetrazole (PTZ), thiosemicarbazide (TSC) convulsion and maximal electroshock-induced seizure (MES).^{33–36} The MES

and PTZ models have been proven useful for detecting the anti-seizure effects of drugs in healthy rodents.^{37,38} The MES test is one of the most useful pharmacological tools for the discovery of new anticonvulsants, given that it enables the identification of compounds that can prevent the spread of seizures. From a clinical point of view, the MES test is an animal model of human tonic-clonic epilepsy.³⁹ The PTZ test is another very common rodent model of generalized absence epilepsy in humans. This test detects the ability of a test compound to increase the chemoconvulsant-induced seizure threshold of an animal, thus protecting it from exhibiting clonic, forebrain seizures.⁴⁰ PTZ is a common convulsant used in animal models to investigate the mechanisms of seizures. The model of TSC seizures (affecting the exchange of GABA) causes clonic seizures similar to pentylenetetrazole seizures. The side effects of the compounds, neurotoxicity (movement coordination disorder, myorelaxation and ataxia), were also studied using the “rotating rod”³³ test on mice. The well-known antiepileptic drug ethosuximide and the tranquilizer diazepam were used as reference drugs.⁴¹

The investigation revealed that all the hybrids displayed pentylenetetrazole antagonism, which ranged from 40% to 80%. Compounds **6d**, **k**, and **m** and **10a–g** at the studied doses of 25 and 50 mg kg^{−1} showed weak activity of up to 40%, respectively, and therefore they were not studied more deeply in other tests and are not presented in the tables. Compounds **6a–c**, **e–j**, **l**, and **n–q** showed superior anticonvulsant activity compared to ethosuximide in the PTZ antagonism test, but were inferior to diazepam (Table 3 and Chart 1). Furthermore, at higher doses (50, 200, and 500 mg kg^{−1}), they did not induce muscle relaxation, being low-toxic with daily toxicity between 630–870 mg kg^{−1} and therapeutic index (TI) much better that of ethosuximide (Table 3).

The structure–activity relationship for anticonvulsant activity by antagonism to pentylenetetrazole revealed that the presence of pyrano[3,4-*c*]pyridine as a substituent on both piperazine and the triazole ring (compounds **6n**) is beneficial for the anticonvulsant activity. The introduction of 8-(furan-2-yl)-6-methoxy-3,3-dimethyl-3,4-dihydro-1*H*-pyrano[3,4-*c*]pyridine-5-carbonitrile in the triazole ring and 1-(furan-2-yl)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile on the triazole ring (compound **6p**) slightly decreased the activity. The same activity was observed for compound **6e**. Compound **6e** has a 5,6,7,8-tetrahydroisoquinoline substituent on the piperazine ring. Replacement of the methyl group with furanyl in compound **6e** from 3-methoxy-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile and Me group of 1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile by propyl or furanyl led to the formation of compounds **6c** and **6l** with decreased activity, respectively. The introduction of a bulkier substituent in position 1 of the pyridine ring as well as cyclohexane ring by cyclopentane in general led to less active compounds (Fig. 2).

The study of 14 the most active compounds (**6a–c**, **e–j**, **l**, and **n–q**) on the model of thiosemicarbazide (TSC) seizures demonstrated that at the dose of 100 mg kg^{−1} they increased the latency of thiosemicarbazide seizures to 1.9–4.65 times



Table 2 Target hybrids linked with a 1,2,4-triazole unit (10a–g)

No.	Hybrids	No.	Hybrids
10a		10e	
10b		10f	
10c		10g	
10d			

Table 3 Anticonvulsant activity and toxicity of the examined hybrids 6a–c, e–j, l, and n–q ^a

Compound	ED ₅₀ * mg kg ⁻¹ (by PTZ antagonism)	TD ₅₀ * mg kg ⁻¹	LD ₅₀ * mg kg ⁻¹	TI	Latency of convulsions, induced by TSC, min	
					M ± M	I**
Control	—	—	—	—	13.0 ± 2.59	1.0
6a	34 (28.3 ÷ 40.8)	>500	800 (666.7 ÷ 960)	23.5	39.0 ± 4.2	3.0
6b	35 (29.7 ÷ 41.3)	>500	750 (630 ÷ 892.5)	21.4	25.0 ± 4.1	1.92
6c	28 (24.3 ÷ 32.2)	>500	820 (683 ÷ 984)	29.3	41.2 ± 1.61	3.17
6e	22 (18.9 ÷ 25.5)	>500	815 (690.6 ÷ 962)	37.0	52.6 ± 1.11	4.05
6f	32 (26.7 ÷ 38.4)	>500	650 (541.6 ÷ 780)	20.3	28.4 ± 1.67	2.18
6g	30 (25.2 ÷ 35.7)	>500	720 (600 ÷ 864)	24.0	25.2 ± 1.2	1.9
6h	34 (28.1 ÷ 41.1)	>500	630 (538.5 ÷ 737)	18.5	41.0 ± 2.75	4.1
6i	41 (34.2 ÷ 49.2)	>500	790 (675 ÷ 924)	19.3	41.0 ± 3.95	3.15
6j	27 (22.9 ÷ 31.9)	>500	830 (686 ÷ 1004)	30.7	36.4 ± 1.11	2.8
6l	28 (22.8 ÷ 34.4)	>500	850 (692 ÷ 1020)	30.4	41.2 ± 1.61	3.17
6n	20 (16.7 ÷ 24.0)	>500	870 (757 ÷ 1001)	43.5	30.4 ± 1.1	2.34
6o	30 (25.0 ÷ 36.0)	>500	800 (656 ÷ 891)	26.7	60.4 ± 5.2	4.65
6p	22 (18.6 ÷ 26.0)	>500	730 (598 ÷ 845)	33.2	39.4 ± 1.11	3.03
6q	29 (24.4 ÷ 34.5)	>500	750 (615 ÷ 891)	25.9	35.8 ± 4.34	2.75
Ethosuximide	155 (117.5 ÷ 204.5)	520 (413 ÷ 655)	1325 (1200 ÷ 1462)	8.5	28.0 ± 1.4	2.15
Diazepam	0.5 (0.4 ÷ 0.7)	2.7 (1.4 ÷ 5.5)	180 (128.5 ÷ 252)	360	9.0 ± 2.5	0.7

^a *indicates $P \leq 0.05$ at a probability level; ** index of latent period of TSC seizures.



Anticonvulsant activity




Chart 1 Graphical representation of the anticonvulsant activity and TI of hybrids **6a–c**, **e–j**, **l**, and **n–q**. The ordinate axis shows the obtained data on PTZ activity and the therapeutic index values, and the abscissa axis shows the number of compounds.

compared to the control, similar to ethosuximide (Table 3). Diazepam was not effective in this model. The most active compounds in this test appeared to be **6o** and **6e**. Both

compounds have a 1-methyl-5,6,7,8-tetrahydroisoquinoline substituent on the piperazine ring. Alternatively, these compounds did not cause any protection tonic and clonic seizures in the MES test.

To evaluate the influence of the most active compounds on the locomotory activity and anxiety of animals, the “open field test”^{42,43} and “elevated plus maze” (EPM)^{44,45} were used. The results for the activity of the compounds in the “open field” model are shown in Table 4. An increase in the number of horizontal (especially compounds **6b**, **c**, and **f**) and vertical movements (especially compounds **6h**, **n**, and **o**) was observed, indicating the activating effect of the compounds. The same behavior was observed for diazepam, whereas not ethosuximide. In contrast to the control and ethosuximide, similar to diazepam, all the studied compounds showed an increase the number of cells examined. This indicates the anxiolytic (anti-anxiety) activity of the compounds, which was especially pronounced in compounds **6f**, **h**, **j**, **l**, **n** and **p**. Diazepam at




Fig. 2 Structure–activity relationship for the anticonvulsant activity via antagonism towards pentylenetetrazole for compounds **6**.

Table 4 Activity of compounds **6a–c**, **e–j**, **l**, and **n–q** and compared drugs in the “open field” model^a

Compound, dose 50 mg kg ⁻¹	Amount (absolute data during 5 min)*		
	Horizontal displacement	Vertical displacement	Cells examination
Control	10.6 ± 2.25	2.0 ± 0.5	1.6 ± 0.6
6a	50.8 ± 8.1**	5.2 ± 2.3**	6.8 ± 2.4**
6b	192.0 ± 10.8**	5.4 ± 1.03**	6.2 ± 1.6**
6c	196.6 ± 15.8**	4.8 ± 2.1**	5.4 ± 1.2**
6e	49.8 ± 4.9**	5.4 ± 1.7**	6.0 ± 1.7**
6f	216.0 ± 17.2**	8.2 ± 2.3**	8.6 ± 3.5**
6g	105.0 ± 12.1**	5.6 ± 0.8**	6.2 ± 2.2**
6h	58.4 ± 7.5**	9.0 ± 4.0**	9.4 ± 1.9**
6i	37.0 ± 6.3**	5.0 ± 1.3**	3.8 ± 1.2**
6j	49.0 ± 9.58**	7.8 ± 1.9**	11.4 ± 3.5**
6l	71.2 ± 12.2**	8.4 ± 2.5**	11.8 ± 2.8**
6n	39.4 ± 5.4**	13.2 ± 1.36**	19.2 ± 3.8**
6o	30.2 ± 4.61**	8.8 ± 1.61**	7.4 ± 2.42**
6p	58.8 ± 7.4**	3.8 ± 0.4**	15.8 ± 1.1**
6q	47.8 ± 7.37**	5.0 ± 0.8**	6.6 ± 1.8**
Ethosuximide (200 mg kg ⁻¹)	16.8 ± 5.51	2.6 ± 1.8	0.8 ± 0.5
Diazepam (2 mg kg ⁻¹)	33.6 ± 6.1**	6.4 ± 1.4**	5.0 ± 1.2**

^a * $P \leq 0.05$ at a probability level. **The differences are statistically significant compared with the control.






Chart 2 Graphical representation of the activity of compounds **6a–c**, **e–j**, **l**, and **n–q**, ethosuximide and diazepam in the “open field” model. The ordinate axis shows the obtained data in the “open field” model and the abscissa axis shows the number of compounds.

a dose of 2 mg kg⁻¹ has the same properties, in contrast to ethosuximide, but is inferior to all these compounds. The most active compound, as in the previous PTZ test, showing the greatest effect was compound **6n**, with two pyrano[3,4-*c*]pyridine rings. The second active compound was **6p**, which has a 2-fury substituent on both pyridine rings (Chart 2).

Regarding the elevated plus-maze (EPM) model, the control animals were mainly situated in the closed arms (Table 5), while the compounds (except compounds **6a**, **f** and **l**) as well as both reference drugs increased the time spent by the experimental animals in the center. Simultaneously, they reduced the stay and number of entries into the closed arms (Chart 3).

Administration of all the compounds was beneficial given that the experimental animals entered the open arms and stayed there for 15.0 (**6g**) to 68.0 (**6h**) s, in contrast to the control animals and those who received ethosuximide at a dose of 200 mg kg⁻¹. This is an indication of an anxiolytic effect. The

most active compound was found to be **6h**, which contains two 5,6,7,8-tetrahydroisoquinoline rings in its structure.

The antidepressant activity of selected compounds was studied using the “forced swim” method⁴⁶ at a dose of 50 mg kg⁻¹. It was found that compounds **6a**, **f**, **g**, **i**, **o** and **p** increased the latent period of the first immobilization (Table 6) compared to the control mice (52 s after the first immobilization), which indicates a certain antidepressant effect. Diazepam at a dose of 2 mg kg⁻¹ acted similarly to these compounds, increasing the latent time of first immobilization, while in the case of ethosuximide at a dose of 200 mg kg⁻¹, it behaved similarly to the control. Alternatively, compounds **6a**, **e**, and **h** and ethosuximide increased, while diazepam reduced the total immobilization time, increasing the total swimming time. However, compounds **6b**, **c**, **f**, **g**, **j**, **n** and **q** exhibited a pronounced antidepressant effect, leading to an increase in the total swimming time, among which, after the introduction of compounds **6b**, **c**,

Table 5 Influence of compounds **6a–c**, **e–j**, **l**, and **n–q** and compared drugs on the EPM model (5 min of research)^a

Compound, 50 mg kg ⁻¹	Time spent in closed arms/s*	Number of entries into the closed arms*	Time spent in the center/s*	Time spent in the open arms/s*
Control	275.0 ± 9.4	4.8 ± 1.6	25.0 ± 3.1	0
6a	245.6 ± 14.6**	3.4 ± 1.1	31.4 ± 4.0	23.0 ± 2.1**
6b	173.0 ± 15.67**	2.8 ± 1.4	64.0 ± 4.7**	63.0 ± 6.1**
6c	169.8 ± 8.12**	3.6 ± 0.8	105.2 ± 23.62**	25.0 ± 3.2**
6e	217.4 ± 16.3**	3.0 ± 0.8	65.0 ± 7.1**	17.6 ± 2.0**
6f	236.0 ± 13.5**	2.8 ± 1.1**	27.0 ± 5.6	37.0 ± 5.3**
6g	250.0 ± 12.4**	1.2 ± 0.6**	35.0 ± 2.4**	15.0 ± 2.4**
6h	175.0 ± 10.2**	2.6 ± 0.6	57.0 ± 5.6**	68.0 ± 8.43**
6i	200.0 ± 24.2**	2.8 ± 2.1**	81.0 ± 5.8**	19.0 ± 3.1**
6j	207.8 ± 16.2**	2.0 ± 2.1	53.4 ± 5.8**	38.8 ± 4.7**
6l	231.0 ± 13.1**	3.0 ± 1.2	30.4 ± 5.2	39.0 ± 5.4**
6n	206.0 ± 11.2**	3.2 ± 1.03	62.2 ± 13.8**	31.8 ± 3.78**
6o	237.0 ± 13.7**	2.4 ± 1.2	38.8 ± 3.4**	24.2 ± 3.5**
6p	226.4 ± 13.4**	3.0 ± 1.59	44.2 ± 5.1**	29.4 ± 4.59**
6q	227.0 ± 15.1**	3.0 ± 0.67	50.0 ± 7.2**	23.0 ± 5.51**
Ethosuximide (200 mg kg ⁻¹)	247.2 ± 15.0	8.1 ± 2.5	52.8 ± 4.7**	0
Diazepam (2 mg kg ⁻¹)	257.5 ± 15.2	5.5 ± 1.1**	42.5 ± 3.9**	57.0 ± 4.2**

^a *P ≤ 0.05 at a probability level. ** The differences are statistically significant compared with the control.



Influence of compounds on the EPM model




Chart 3 Graphical representation of the influence of compounds 6a–c, e–j, l, and n–q and compared drugs on the EPM model (5 min of research). The ordinate axis shows the obtained data on the EPM model and the abscissa axis shows the number of compounds.

j, **n** and **q**, there was complete swimming for 6 min. Also, compounds **6n** and **6q** were the most active in this test (Chart 4).

For the evaluation of learning and memory in rodent models of CNS disorders, the model of electroshock retrograde amnesia, conditioned response of passive avoidance (CRPA) (Table 7), was used.⁴⁷ During 6 min of the experiment, the control rats on the 1st and 2nd day remained in the light compartment for almost the entire period (280.0 s), while with the administration of the compounds at a dose of 50 mg kg⁻¹, they somehow increased the time of reproduction of the reflex in animals similar to the nootropic drug piracetam in a day (Table 7). This indicates the anti-amnesic effect of the chosen hybrid derivatives. The results obtained are very close, although

they are statistically significant, and therefore are not presented in graphical form.

2.3. Molecular docking

2.3.1. Docking to GABAA receptor – prediction of the mechanism of anticonvulsant and anxiolytic activity. Antiepileptic medications frequently target GABAA receptors to inhibit sodium channels or enhance aminobutyric acid (GABA) activity.^{48,49} Docking studies of all the tested compounds were carried out to gain insight into their interactions in the GABAA receptor active site and better understand the molecular basis of the inhibitory activity of GABAA receptors.

Table 6 Effect of compounds 6a–c, e–j, l, and n–q and reference preparations on “forced swim” (study for 6 min)^a

Compound, dose 50 mg kg ⁻¹	Latent period first immobilization (s)	Total time of active swimming (s)*	Total time of immobilization (s)*
Control	52.0 ± 5.4	318.0 ± 8.36	42.0 ± 7.24
6a	79.0 ± 7.8**	276.4 ± 6.2**	84.0 ± 3.2**
6b	0**	360.0 ± 0.2**	0**
6c	0**	360.0 ± 0.2**	0**
6e	52.0 ± 6.3	296.0 ± 16.85	66.0 ± 4.48**
6f	72.0 ± 6.3**	357.0 ± 13.5**	3.0 ± 0.6**
6g	73.0 ± 5.8**	358.0 ± 8.2**	2.0 ± 0.8**
6h	58.0 ± 7.1	288.0 ± 8.35	84.0 ± 5.04**
6i	66.9 ± 5.3**	346.0 ± 11.35**	14.0 ± 3.37**
6j	0**	360.0 ± 0.2**	0**
6l	53.0 ± 7.4	324.0 ± 12.4	42.0 ± 12.04
6n	0**	360.0 ± 0.2**	0**
6o	68.5 ± 7.2**	336.0 ± 25.3**	24.0 ± 2.9**
6p	70.0 ± 7.3**	345.0 ± 18.55	15.0 ± 2.55**
6q	0**	360.0 ± 1.64**	0**
Ethosuximide (200 mg kg ⁻¹)	55.0 ± 10.1	262 ± 25.0	98.0 ± 9.2
Diazepam (2 mg kg ⁻¹)	74.0 ± 8.7**	336.0 ± 8.1**	24.0 ± 8.2**

^a *P ≤ 0.05 at a probability level. **The differences are statistically significant compared with the control.



Effect of compounds on "forced swimming"




Chart 4 Graphical representation of the effect of compounds 6a–c, e–j, l, and n–q and reference preparations on "forced swim" (study for 6 min). The ordinate axis shows the obtained data on "forced swim" and the abscissa axis shows the number of compounds.

Table 7 Characterization of the parameters of amnesic functions on the model of electroshock retrograde amnesia after administration of hybrid compounds 6a–c, e–j, l, and n–q (study for 5 min)^a

Compound, dose 50 mg kg ⁻¹	The time spent in the light chamber during the training of CRPA (s), first day	The time spent in the light chamber when playing CRPA + MESH after 24 hours (s), second day
Control	280.0 ± 7.5	281.0 ± 6.1
6a	283.0 ± 9.3	297.4 ± 6.1**
6b	281.0 ± 8.6	297.0 ± 6.5**
6c	281.0 ± 7.4	299.0 ± 8.1**
6e	285.8 ± 5.2	301.0 ± 7.1**
6f	287.0 ± 7.2	297.2 ± 5.8**
6g	282.0 ± 7.7	299.0 ± 8.4**
6h	283.9 ± 8.9	300.0 ± 7.7**
6i	280.0 ± 8.0	298.4 ± 5.3**
6j	286.0 ± 7.3	297.0 ± 5.3**
6l	285.0 ± 6.5	296.4 ± 5.3**
6n	285.0 ± 8.1	295.4 ± 5.3**
6o	281.0 ± 7.4	297.0 ± 5.3**
6p	283.0 ± 5.8	298.0 ± 5.3**
6q	284.0 ± 6.3	296.2 ± 3.3**
Diazepam (2 mg kg ⁻¹)	187.0 ± 6.7*	126.0 ± 6.5**
Piracetam (1000 mg kg ⁻¹)	158.0 ± 5.9*	243.7 ± 8.4**

^a CRPA + MESH – conditioned reaction of passive avoidance + maximal electric shock; * significant differences in values from the intact control without MES; ** significant differences in values from the control with MES at $P \leq 0.05$.

In the docking studies, the crystal structure of the GABAA receptor was acquired from the Protein Data Bank (PDB) using PDB ID: 4COF.⁵⁰ The resolution, R , and R free values for the X-




Fig. 3 Alignment of the docked conformation of the re-docked initial inhibitor benzamidine (blue) and the co-crystallized ligand to the 4COF structure (RMSD: 0.34 Å).


ray diffraction structure of the GABAA receptor were 2.97, 0.206, and 0.226, respectively. The initial co-crystal ligand benzamidine was removed and re-docked at the catalytic site of the protein using the same parameters and preparation procedure of as that used for the tested compounds as the first step in the docking studies and for their validation. The root-mean-square deviation (RMSD) of the co-crystal and re-docked pose was found to be 0.34 (Fig. 3).

Table 8 displays the docking analysis results. According to the obtained results, compound 6n forms three hydrogen bonds with the Tyr97 (N···H, 3.35), Thr202 (O···H, 2.78), and Ala201 (N···H, 3.73) residues, while diazepam only forms one hydrogen bond with Thr202 (N···H, 2.67), as shown in Fig. 4 for the latter and Fig. 5 for the former. The benzene moiety of the molecule interacts hydrophobically with the Thr176 and Phe200 residues, further stabilizing the complex ligand-enzyme.



Table 8 Molecular docking into the GABA_A receptor

No.	Est. binding energy (kcal mol ⁻¹)	I-H	Residues involved in hydrogen bond formation	Hydrophobic interactions	Aromatic interactions
6a	-6.89	1	Thr202 (O⋯H, 3.98 Å), Tyr205 (N⋯H, 2.77 Å)	Ala25, Leu99, Phe200	—
6b	-6.35	—	—	Thr176, Tyr205	—
6c	-8.30	1	Thr202 (O⋯H, 3.29 Å)	Thr176, Phe200, Ala201	Phe200
6d	-6.45	—	—	Thr176, Phe200	—
6e	-10.72	3	Tyr97 (N⋯H, 3.25 Å), Thr202 (O⋯H, 3.56 Å), Tyr205 (N⋯H, 2.94 Å)	Thr176, Ala201, Phe200	—
6f	-7.02	1	Tyr97 (O⋯H, 3.42 Å)	Phe200	—
6g	-7.10	1	Thr202 (N⋯H, 3.20 Å)	Tyr62, Phe200	—
6h	-6.78	—	—	Thr176, Ala201, Tyr205	—
6i	-6.20	—	—	Tyr157, Tyr205	—
6j	-9.81	2	Tyr97 (N⋯H, 3.78 Å), Thr202 (O⋯H, 3.26 Å)	Ala201, Tyr205	—
6k	—	—	—	—	—
6l	-9.48	2	Thr202 (N⋯H, 2.79 Å), Tyr205 (N⋯H, 2.88 Å)	Ile42, Tyr62, Leu99, Phe200, Ala201	Phe200
6m	—	—	—	—	—
6n	-11.54	3	Tyr97 (N⋯H, 3.35 Å), Thr202 (O⋯H, 2.78 Å), Ala201 (N⋯H, 3.73 Å)	Ile42, Tyr97, Leu99, Thr176, Phe200, Ala201	—
6o	-8.11	1	Thr202 (O⋯H, 3.76 Å)	Thr176, Phe200	—
6p	-9.97	2	Tyr97 (N⋯H, 3.54 Å), Thr202 (O⋯H, 3.11 Å)	Thr176, Ala201, Phe200, Tyr205	—
6q	-8.25	1	Thr202 (O⋯H, 3.49 Å)	Phe200, Ala201	—
Diazepam	-8.90	1	Thr202 (N⋯H, 2.67 Å)	Tyr62, Thr176, Phe200, Ala201, Tyr205	Phe200

Fig. 4 Docked conformation of diazepam and the GABA_A receptor complex.

2.3.2. Docking to SERT and 5-HT_{1A} receptor. Tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) are the two primary categories of antidepressant drugs.⁵¹ By blocking the serotonin (5-HT) transporter (SERT), these drugs prevent the entry of serotonin in the pre-synaptic neurons. By removing serotonin from the pre-synaptic neurons, the *trans*-membrane protein SERT prevents serotonergic neurotransmission. The 5-HT_{1A} receptors are activated by an increase in serotonin, which reduces serotonergic neurotransmission and delays the beginning of antidepressant activity.^{52,53} This delay continues until the HT_{1A} receptors are desensitized and serotonin release returns to normal.


Fig. 5 Docked pose of compound 6n and the GABA_A receptor complex. Red lines show hydrogen bonds and yellow spheres represent hydrophobic interactions.

Table 9 Molecular docking in SERT (PDB ID: 3F3A)

No.	Est. binding energy (kcal mol ⁻¹)	I-H	Residues involved in hydrogen bond formation	Residues involved in hydrophobic interactions	Residues involved in aromatic interactions
6a	-4.92	—	—	—	—
6b	-9.11	—	Arg11 (N⋯H, 2.52 Å)	His7, Arg431	—
6c	-9.48	—	Arg11 (N⋯H, 3.57 Å), Lys443 (N⋯H, 3.54 Å)	His7, Arg431	—
6d	-5.24	—	—	His7, Arg431	—
6e	-6.95	1	His7 (N⋯H, 3.51 Å)	Asp267, Gly433	—
6f	-6.45	1	His7 (N⋯H, 3.85 Å)	Asp267	—
6g	-7.08	1	His7 (N⋯H, 3.23 Å)	Asp267, Gly433	Lys264
6h	-5.52	—	—	Asp267, Arg431	—
6i	-5.20	—	—	Gly432	—
6j	-8.26	1	Gln266 (N⋯H, 2.96 Å)	Asp267, Gly432, Gly433	—
6k	-6.58	1	His7 (N⋯H, 3.23 Å)	Asp267, Gly433	—
6l	-6.79	1	Gln266 (N⋯H, 3.54 Å)	His7, Asp267	—
6m	-5.02	—	—	Arg431	—
6n	-9.65	—	Arg11 (N⋯H, 3.02 Å), His7 (O⋯H, 3.16 Å)	Asp267, Ile441	—
6o	-4.26	—	—	His7, Gly433	—
6p	-4.15	—	—	—	—
6q	-9.87	—	Arg11 (N⋯H, 2.43 Å), Asp272 (O⋯H, 3.12 Å)	Ala9, Ile441	—

After accounting for all the previously mentioned variables, we proceeded with the docking studies of SERT and 5-HT_{1A} receptor to ascertain whether the investigated compounds function as dual inhibitors of the serotonin transporter (SERT) and pre-synaptic auto inhibitory 5-HT_{1A} receptors.

We used the X-ray crystal structure of LeuT coupled to L-tryptophan (PDB code: 3F3A), a prokaryotic homologue of SERT, given that no crystal structure of SERT is available in the Protein Data Bank (PDB).⁵⁴ Table 9 displays the results of the docking studies in SERT.

Initially, as a step in the docking experiments and for the validation of the docking parameters, the co-crystal ligand L-tryptophan was removed and re-docked at the protein binding site using the same parameters as that utilized for the tested drugs. The RMSD of 0.86 was found between the co-crystal and re-docked poses, as shown in Fig. 6.

Compound **6q**, which forms two hydrogen bonds, had the best docking score. The first hydrogen bond is 2.43 Å between the nitrogen atom of the side chain of Arg11 and the hydrogen atom, and the other is 3.12 Å between the oxygen atom of the C=O group and the hydrogen of the side chain of Asp272 (Fig. 7). Thus, the experimental data and the docking results are in agreement.




Fig. 6 Alignment of the docked conformation of the re-docked initial inhibitor L-tryptophan (blue) and the co-crystallized 3F3A structure (magenta, RMSD: 0.86 Å).

Docking to the 5-HT_{1A} receptor was done using the crystal structure of the human 2-adrenergic receptor in conjunction with the antagonist alprenolol (PDB code: 3NYA).^{55,56} To validate the docking parameters, the original co-crystal ligand alprenolol was re-docked at the catalytic region of the protein. The RMSD (root-mean-square deviation) between the co-crystal and re-docked poses was 0.98 (Fig. 8).

The orthosteric binding site of the 5-HT_{1A} receptor was docked with all the substances studied (Table 10), and compound **6q** (-12.12 kcal mol⁻¹) was formed the best docking score because it forms four hydrogen bonds with the Phe193, Thr195, and Tyr316 residues. Alprenolol also forms a hydrogen bond with Tyr316. This compound also shows hydrophobic interactions with the Trp109, Phe193, Tyr199, Thr110, Ala200, Phe289, and Tyr316 residues (Fig. 9A). According to Fig. 9B, it is obvious that compound is situated in the same cavity of the enzyme, similar to alprenolol, which can explain the high activity of compound **6q**. Finally, according to the docking results, this compound can be a dual target given that it is a good inhibitor of SERT as well as 5-HT_{1A} receptor binder.

3. Materials and methods

3.1. Chemistry

3.1.1. General information. ¹H and ¹³C NMR spectra were recorded in DMSO-*d*₆/CCl₄ (1/3) solution (300 MHz and 75 MHz, respectively) on a Mercury 300VX spectrometer (Varian Inc., Palo Alto, CA, USA). Chemical shifts are reported as δ (parts per million) relative to TMS as the internal standard. IR spectra were recorded on a Nicolet Avatar 330-FT-IR spectrophotometer (Thermo Nicolet, CA, USA) in Vaseline, with ν_{\max} in cm⁻¹. MS spectra were recorded on a Waters Q-ToF. Melting points were determined on a MP450 melting point apparatus. Elemental analyses were performed on an Elemental Analyzer Euro EA






Fig. 7 (A) Docked pose of compound **6q** and the SERT complex. (B) 2D ligand interaction diagram for the docked ligand.




Fig. 8 Alignment of the docked conformation of the re-docked initial inhibitor alprenolol (blue) and the co-crystallized ligand (green) to the 3NYA structure (RMSD: 0.98 Å).

3000. Compounds **2b**, **3b**, **6a**, **j**, and **m**;¹⁶ **5a**, **d**, and **e-g**;^{16,17} **7a** and **b**,³¹ and **7c**,³² were previously described.

3.1.1.1. General procedure for the synthesis of compounds 2a and c-e. To a stirred solution of compound **1** (5 mmol) and triethylamine (0.84 mL, 6 mmol) in benzene (50 mL), chloroacetyl chloride (4.8 mL, 6 mmol) was added dropwise. The reaction mixture was maintained at 35 °C for 6 h. Then the reaction mixture was cooled at room temperature, the solvent was removed under vacuum and water (50 mL) was added. The

Table 10 Molecular docking free binding energy (kcal mol⁻¹) in the 5-HT_{1A} receptor (PDB ID: 3NYA)

No.	Est. binding energy (kcal mol ⁻¹)	I-H	Residues involved in hydrogen bond formation	Residues involved in hydrophobic interactions	Residues involved in aromatic interactions
6a	-4.40	—	—	—	—
6b	-10.12	1	Asn312 (N···H, 2.89 Å)	Trp109, Phe193, Ala200, Phe289, Tyr316	—
6c	-9.94	2	Thr195 (O···H, 3.15 Å), Tyr316 (O···H, 2.88 Å)	Thr118, Ala200, Asn312	—
6d	-5.08	—	—	Trp286, Asn312	—
6e	-5.37	—	—	—	—
6f	-6.10	—	—	Trp286	—
6g	-7.02	1	Tyr316 (O···H, 3.16 Å)	Thr118, Ala200, Asn312	—
6h	-5.03	—	—	Ala200, Tyr308	—
6i	-4.19	—	—	Trp286	—
6j	-9.25	1	Tyr308 (N···H, 2.53 Å)	Trp286, Asn312	—
6k	-4.10	—	—	—	—
6l	-2.79	—	—	—	—
6m	-5.02	—	—	Arg431	—
6n	-11.65	3	Tyr118 (O···H, 2.72 Å), Ser204 (N···H, 3.53 Å), Tyr316 (N···H, 3.71 Å)	Trp109, Ile309, Tyr308, Phe193, Val114, Tyr110, Ile201, Ala200	—
6o	-4.20	—	—	Thr118, Ala200	—
6p	-4.82	—	—	Thr118, Ala200, Asn312	—
6q	-12.12	4	Phe193 (O···H, 2.75 Å), Phe193 (N···H, 2.62 Å), Thr195 (O···H, 3.02 Å), Tyr316 (O···H, 2.53 Å)	Trp109, Phe193, Tyr199, Thr110, Ala200, Phe289, Tyr316	Phe193
Alprenolol	-13.19	4	Asp113, Asn312, Tyr316	Tyr118, Ala200, Tyr308	—






Fig. 9 (A) 2D ligand interaction diagram for docked compound **6q**. (B) Docked pose of compound **6q** (blue) and alprenolol (magenta) into the 5-HT_{1A} receptor.

resulting crystals were filtered, washed with water, dried and recrystallized from ethanol.

3.1.1.1.1. 3-[4-(Chloroacetyl)piperazin-1-yl]-1-propyl-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile (2a). The reaction between compound **1a** and chloroacetyl chloride produced a white solid in 77% yield; mp 114–116 °C; IR ν/cm^{-1} : 1654 (C=O), 2208 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 0.97 (t, *J* = 7.4 Hz, 3H, CH₂CH₃), 1.64–1.77 (m, 2H, CH₂CH₃), 2.09–2.20 (m, 2H, 6-CH₂), 2.55–2.61 (m, 2H, CH₂C₂H₅), 2.84 (t, *J* = 7.5 Hz, 2H, 7-CH₂), 3.01 (t, *J* = 7.6 Hz, 2H, 5-CH₂), 3.54–3.70 (m, 8H, C₄H₈N₂), 4.22 (s, 2H, CH₂Cl). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 13.50, 20.41, 23.52, 29.14, 32.43, 37.05, 40.79, 41.10, 45.09, 47.69, 48.32, 90.31, 115.97, 129.08, 158.52, 159.08, 160.13, 164.18. Anal. calcd for C₁₈H₂₃ClN₄O: C 62.33%; H 6.68%; N 16.15%. Found: C 62.73%; H 6.90%; N 16.44%.

3.1.1.1.2. 3-[4-(Chloroacetyl)piperazin-1-yl]-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (2c). The reaction between compound **1c** and chloroacetyl chloride produced a white solid in 77% yield; mp 128–130 °C; IR ν/cm^{-1} : 1655 (C=O), 2215 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.76–1.88 (m, 4H, 6,7-CH₂), 2.35 (s, 3H, CH₃), 2.53–2.59 (m, 2H, 8-CH₂), 2.80–2.86 (m, 2H, 5-CH₂), 3.49–3.70 (m, 8H, C₄H₈N₂), 4.20 (s, 2H, CH₂Cl). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 21.10, 21.90, 22.12, 24.64, 27.92, 40.76, 41.18, 45.17, 47.86, 48.37, 94.03, 115.74, 122.64, 150.83, 158.62, 158.81, 164.16. Anal. calcd for C₁₇H₂₁ClN₄O: C 61.35%; H 6.36%; N 16.83%. Found: C 61.67%; H 6.53%; N 17.08%.

3.1.1.1.3. 3-[4-(Chloroacetyl)piperazin-1-yl]-1-isopropyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (2d). The reaction between compound **1d** and chloroacetyl chloride produced a white solid in 75% yield; mp 119–121 °C; IR ν/cm^{-1} : 1661 (C=O), 2209 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.17

(t, *J* = 6.7 Hz, 6H, CH(CH₃)₂), 1.77–1.85 (m, 4H, 6,7-CH₂), 2.61–2.68 (m, 2H, 8-CH₂), 2.81–2.88 (m, 2H, 5-CH₂), 3.16 (sp, *J* = 6.7 Hz, 1H, CH(CH₃)₂), 3.52–3.70 (m, 8H, C₄H₈N₂), 4.21 (s, 2H, CH₂Cl). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.90, 21.07, 22.02, 23.82, 28.23, 30.30, 40.76, 41.12, 45.16, 47.65, 48.36, 93.86, 115.79, 121.11, 151.42, 158.87, 164.15, 165.98. Anal. calcd for C₁₉H₂₅ClN₄O: C 63.24%; H 6.98%; N 15.53%. Found: C 63.62%; H 7.19%; N 15.81%.

3.1.1.1.4. 3-[4-(Chloroacetyl)piperazin-1-yl]-1-(2-furyl)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (2e). The reaction between compound **1e** and chloroacetyl chloride produced a brown solid in 84% yield; mp 186–188 °C; IR ν/cm^{-1} : 1676 (C=O), 2210 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.77–1.90 (m, 4H, 6,7-CH₂), 2.88–3.01 (m, 4H, 8,5-CH₂), 3.54–3.73 (m, 8H, C₄H₈N₂), 4.23 (s, 2H, CH₂Cl), 6.56 (dd, *J* = 3.5, 1.7 Hz, 1H, 4-CH_{fur}), 7.08 (dd, *J* = 3.5, 0.8 Hz, 1H, 3-CH_{fur}), 7.68 (dd, *J* = 1.7, 0.8 Hz, 1H, 5-CH_{fur}). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.90, 22.00, 25.51, 28.59, 40.83, 41.12, 45.12, 47.77, 48.36, 94.94, 111.30, 113.52, 115.70, 121.17, 143.80, 147.19, 153.15, 153.20, 158.44, 164.23. Anal. calcd for C₂₀H₂₁ClN₄O₂: C 62.42%; H 5.50%; N 14.56%. Found: C 62.79%; H 5.96%; N 14.83%.

3.1.1.2. General procedure for the synthesis of compounds 3a and c-e. A mixture of compound **2** (5 mmol) and sodium azide (0.65 g, 10 mmol) in acetone (50 mL) was heated at refluxing for 15 h. After filtration, the solvent was evaporated and water (50 mL) was added. The resulting crystals were filtered, washed with water, dried, and recrystallized from ethanol.

3.1.1.2.1. 3-[4-(Azidoacetyl)piperazin-1-yl]-1-propyl-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile (3a). The reaction between compound **2a** and sodium azide produced a white solid in 84%; mp 122–124 °C; IR ν/cm^{-1} : 1651 (C=O), 2109 (N₃), 2210 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 0.96 (t, *J*



= 7.4 Hz, 3H, CH₂CH₃), 1.64–1.77 (m, 2H, CH₂CH₃), 2.09–2.20 (m, 2H, 6-CH₂), 2.55–2.61 (m, 2H, CH₂C₂H₅), 2.84 (t, *J* = 7.5 Hz, 2H, 7-CH₂), 3.00 (t, *J* = 7.6 Hz, 2H, 5-CH₂), 3.49–3.71 (m, 8H, C₄H₈N₂), 4.05 (s, 2H, CH₂N₃). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 13.50, 20.42, 23.52, 29.14, 32.44, 37.06, 40.97, 43.81, 47.73, 48.19, 49.56, 90.22, 116.00, 129.06, 158.53, 159.07, 160.14, 165.27. Anal. calcd for C₁₈H₂₃N₇O: C 61.17%; H 6.56%; N 27.74%. Found: C 61.51%; H 6.73%; N 27.99%.

3.1.1.2.2. *3-[4-(Azidoacetyl)piperazin-1-yl]-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (3c)*. The reaction between compound **2c** and sodium azide produced a white solid in 81% yield; mp 100–102 °C; IR ν/cm^{-1} : 1655 (C=O), 2106 (N₃), 2210 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.76–1.87 (m, 4H, 6,7-CH₂), 2.35 (s, 3H, CH₃), 2.52–2.59 (m, 2H, 8-CH₂), 2.79–2.85 (m, 2H, 5-CH₂), 3.49–3.56 (m, 6H, C₄H₈N₂), 3.64–3.71 (m, 2H, C₄H₈N₂), 4.05 (s, 2H, CH₂N₃). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 21.11, 21.90, 22.14, 24.64, 27.93, 41.04, 43.88, 47.86, 48.27, 49.55, 93.95, 115.78, 122.61, 150.84, 158.65, 158.81, 165.26. Anal. calcd for C₁₇H₂₁N₇O: C 60.16%; H 6.24%; N 28.89%. Found: C 60.55%; H 6.46%; N 29.17%.

3.1.1.2.3. *3-[4-(Azidoacetyl)piperazin-1-yl]-1-isopropyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (3d)*. The reaction between compound **2d** and sodium azide produced a white solid in 87% yield; mp 116–118 °C; IR ν/cm^{-1} : 1645 (C=O), 2111 (N₃), 2202 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.17 (t, *J* = 6.7 Hz, 6H, CH(CH₃)₂), 1.77–1.85 (m, 4H, 6,7-CH₂), 2.61–2.68 (m, 2H, 8-CH₂), 2.81–2.88 (m, 2H, 5-CH₂), 3.16 (sp, *J* = 6.7 Hz, 1H, CH(CH₃)₂), 3.51–3.60 (m, 6H, C₄H₈N₂), 3.66–3.72 (m, 2H, C₄H₈N₂), 4.04 (s, 2H, CH₂N₃). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.90, 21.06, 22.01, 23.81, 28.22, 30.29, 40.97, 43.84, 47.70, 48.23, 49.55, 93.80, 115.79, 121.07, 151.41, 158.87, 165.19, 165.96. Anal. calcd for C₁₉H₂₅N₇O: C 62.10%; H 6.86%; N 26.68%. Found: C 62.42%; H 7.04%; N 26.92%.

3.1.1.2.4. *3-[4-(Azidoacetyl)piperazin-1-yl]-1-(2-furyl)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (3e)*. The reaction between compound **2e** and sodium azide produced a yellow solid in 85% yield; mp 174–176 °C; IR ν/cm^{-1} : 1655 (C=O), 2103 (N₃), 2213 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.77–1.90 (m, 4H, 6,7-CH₂), 2.88–2.94 (m, 2H, 8-CH₂), 2.95–3.00 (m, 2H, 5-CH₂), 3.52–3.74 (m, 8H, C₄H₈N₂), 4.06 (s, 2H, CH₂N₃), 6.57 (dd, *J* = 3.5, 1.7 Hz, 1H, 4-CH_{furr}), 7.08 (dd, *J* = 3.5, 0.8 Hz, 1H, 3-CH_{furr}), 7.68 (dd, *J* = 1.7, 0.8 Hz, 1H, 5-CH_{furr}). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.89, 22.00, 25.51, 28.57, 40.97, 43.82, 47.80, 48.22, 49.56, 94.86, 111.30, 113.51, 115.71, 121.13, 143.80, 147.18, 153.15, 153.18, 158.44, 165.30. Anal. calcd for C₂₀H₂₁N₇O₂: C 61.37%; H 5.41%; N 25.05%. Found: C 61.73%; H 5.61%; N 25.32%.

3.1.1.3. General procedure for the synthesis of compounds 5b, c, h and i. To a stirred suspension of compound **4** (5 mmol) and potassium carbonate (1.38 g, 10 mmol) in absolute DMF (25 mL), propargyl bromide (0.42 mL, 5.5 mmol) was added dropwise. The reaction mixture was maintained at room temperature for 5 h. After water was added (50 mL), the resulting crystals were filtered, washed with water, dried and recrystallized from ethanol.

3.1.1.3.1. 1-Methyl-3-(prop-2-yn-1-yloxy)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (5b). The reaction between compound **4b** and propargyl bromide produced a white solid in 71% yield; mp 94–96 °C; IR ν/cm^{-1} : 2128 (C≡CH), 2221 (C≡N), 3246, 3269 (≡CH). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3): δ 1.76–1.89 (m, 4H, 6,7-CH₂), 2.41 (s, 3H, CH₃), 2.57–2.62 (m, 2H, 8-CH₂), 2.83–2.88 (m, 2H, 5-CH₂), 2.91 (t, *J* = 2.4 Hz, 1H, ≡CH), 5.02 (d, *J* = 2.4 Hz, 2H, OCH₂). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.84, 21.80, 21.87, 24.62, 27.83, 53.10, 75.85, 78.02, 92.89, 113.29, 124.21, 152.01, 158.32, 159.30. Anal. calcd for C₁₄H₁₄N₂O: C 74.31%; H 6.24%; N 12.38%. Found: C 74.69%; H 6.46%; N 12.67%.

3.1.1.3.2. 1-Ethyl-3-(prop-2-yn-1-yloxy)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (5c). The reaction between compound **4c** and propargyl bromide produced a white solid in 75% yield; mp 84–86 °C; IR ν/cm^{-1} : 2131 (C≡CH), 2220 (C≡N), 3276 (≡CH). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.27 (t, *J* = 7.4 Hz, 3H, CH₂CH₃), 1.76–1.88 (m, 4H, 6,7-CH₂), 2.59–2.65 (m, 2H, 8-CH₂), 2.70 (q, *J* = 7.4 Hz, 2H, CH₂CH₃), 2.85–2.88 (m, 2H, 5-CH₂), 2.87 (t, *J* = 2.4 Hz, 1H, ≡CH), 5.04 (d, *J* = 2.4 Hz, 2H, OCH₂). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 11.04, 20.86, 21.85, 24.02, 27.04, 27.95, 53.06, 75.62, 78.12, 92.73, 113.33, 123.54, 152.12, 159.51, 162.26. Anal. calcd for C₁₅H₁₆N₂O: C 74.97%; H 6.71%; N 11.66%. Found: C 75.30%; H 6.88%; N 11.89%.

3.1.1.3.3. 8-(4-Methoxyphenyl)-3,3-dimethyl-6-(prop-2-yn-1-yloxy)-3,4-dihydro-1H-pyrano[3,4-c]pyridine-5-carbonitrile (5h). The reaction between compound **4h** and propargyl bromide produced a white solid in 70% yield; mp 131–133 °C; IR ν/cm^{-1} : 2121 (C≡CH), 2225 (C≡N), 3268 (≡CH). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.33 (s, 6H, C(CH₃)₂), 2.86 (s, 2H, CH₂), 3.00 (t, *J* = 2.4 Hz, 1H, ≡CH), 3.87 (s, 3H, OCH₃), 4.69 (s, 2H, OCH₂), 5.10 (d, *J* = 2.4 Hz, 2H, OCH₂), 6.95–7.00 (m, 2H, C₆H₄), 7.50–7.57 (m, 2H, C₆H₄). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 26.18, 38.16, 53.50, 54.66, 59.84, 69.15, 76.16, 78.00, 93.62, 112.99, 113.24, 121.54, 129.44, 129.97, 150.66, 155.06, 159.84, 160.04. Anal. calcd for C₂₁H₂₀N₂O₃: C 72.40%; H 5.79%; N 8.04%. Found: C 72.75%; H 5.98%; N 8.30%.

3.1.1.3.4. 8-(2-Furyl)-3,3-dimethyl-6-(prop-2-yn-1-yloxy)-3,4-dihydro-1H-pyrano[3,4-c]pyridine-5-carbonitrile (5i). The reaction between compound **4i** and propargyl bromide produced a light-yellow solid in 72% yield; mp 183–185 °C; IR ν/cm^{-1} : 2127 (C≡CH), 2219 (C≡N), 3276 (≡CH). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.31 (s, 6H, C(CH₃)₂), 2.83 (s, 2H, CH₂), 2.98 (t, *J* = 2.4 Hz, 1H, ≡CH), 5.00 (s, 2H, OCH₂), 5.10 (d, *J* = 2.4 Hz, 2H, OCH₂), 6.63 (dd, *J* = 3.5, 1.7 Hz, 1H, 4-CH_{furr}), 7.28 (dd, *J* = 3.5, 0.7 Hz, 1H, 3-CH_{furr}), 7.76 (dd, *J* = 1.7, 0.7 Hz, 1H, 5-CH_{furr}). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 25.71, 38.34, 53.61, 59.77, 68.43, 76.13, 77.74, 93.86, 111.85, 112.89, 114.30, 119.42, 143.31, 144.94, 151.07, 152.49, 159.49. Anal. calcd for C₁₈H₁₆N₂O₃: C 70.12%; H 5.23%; N 9.09%. Found: C 70.43%; H 5.39%; N 9.31%.

3.1.1.4. General procedure for the synthesis of compounds 6b–i, k, l, n and o–q. Compounds **5** (2 mmol) and the corresponding azides **3** (2.2 mmol) were suspended in a 1 : 1 mixture of water



and *tert*-butyl alcohol (30 mL). Sodium ascorbate (0.04 g, 0.2 mmol, of freshly prepared solution in water) was added, followed by copper(II) sulfate pentahydrate (0.05 g, 0.2 mmol, in water). The mixture was stirred for 10 h at room temperature, and then 10 h at 40–50 °C. After cooling, water was added (50 mL), the precipitate was filtered, washed with water and recrystallized from a mixture of ethanol-chloroform (1 : 3).

3.1.1.4.1. *3-{4-[[4-[[[4-Cyano-1-isopropyl-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]acetyl]piperazin-1-yl]-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (6b).* The reaction between compound **3c** and **5a** produced a light-yellow solid in 72% yield; mp 207–209 °C; IR ν/cm^{-1} : 1660 (C=O), 2193, 2231 (C≡N). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.27 (d, J = 6.8 Hz, 6H, CH(CH $_3$) $_2$), 1.77–1.87 (m, 4H, 6',7'-CH $_2$), 2.13–2.24 (m, 2H, 6-CH $_2$), 2.36 (s, 3H, CH $_3$), 2.53–2.60 (m, 2H, 8'-CH $_2$), 2.80–2.93 (m, 4H, 7,5'-CH $_2$), 3.03 (t, J = 7.6 Hz, 2H, 5-CH $_2$), 3.05 (sp, J = 6.8 Hz, 1H, CH(CH $_3$) $_2$), 3.51–3.74 (m, 8H, C $_4$ H $_8$ N $_2$), 5.47 (s, 2H, OCH $_2$), 5.55 (s, 2H, NCH $_2$), 7.93 (s, 1H, CH $_{\text{triazole}}$). ^{13}C NMR (75 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 20.60, 21.11, 21.91, 22.17, 23.89, 24.64, 27.93, 28.68, 32.00, 32.70, 41.24, 44.00, 47.79, 48.25, 50.33, 59.64, 89.76, 93.89, 113.80, 115.83, 122.58, 125.19, 129.58, 141.78, 150.83, 158.66, 158.82, 161.00, 161.22, 162.60, 163.71. Anal. calcd for C $_{32}$ H $_{37}$ N $_9$ O $_2$: C 66.30%; H 6.43%; N 21.75%. Found: C 66.68%; H 6.65%; N 22.03%.

3.1.1.4.2. *3-[[1-{2-[4-(4-Cyano-1-propyl-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl)piperazin-1-yl]-2-oxoethyl]-1H-1,2,3-triazol-4-yl]methoxy]-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (6c).* The reaction between compound **3a** and **5b** produced a white solid in 86% yield; mp 136–138 °C; IR ν/cm^{-1} : 1673 (C=O), 2217, 2218 (C≡N). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 0.97 (t, J = 7.4 Hz, 3H, CH $_2$ CH $_3$), 1.65–1.77 (m, 2H, CH $_2$ CH $_3$), 1.77–1.88 (m, 4H, 6,7-CH $_2$), 2.10–2.21 (m, 2H, 6'-CH $_2$), 2.45 (s, 3H, CH $_3$), 2.55–2.63 (m, 4H, 8-CH $_2$, CH $_2$ C $_2$ H $_5$), 2.82–2.89 (m, 4H, 5,7'-CH $_2$), 3.02 (t, J = 7.5 Hz, 2H, 5'-CH $_2$), 3.58–3.75 (m, 8H, C $_4$ H $_8$ N $_2$), 5.47 (s, 2H, OCH $_2$), 5.52 (s, 2H, NCH $_2$), 7.95 (s, 1H, CH $_{\text{triazole}}$). ^{13}C NMR (75 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 13.50, 20.41, 20.87, 21.84, 21.94, 23.51, 24.61, 27.81, 29.14, 32.44, 37.06, 41.17, 43.93, 47.62, 48.15, 50.32, 59.30, 90.15, 92.71, 113.65, 116.02, 123.74, 125.51, 128.97, 141.77, 151.93, 158.45, 158.52, 159.05, 160.13, 160.17, 163.73. Anal. calcd for C $_{32}$ H $_{37}$ N $_9$ O $_2$: C 66.30%; H 6.43%; N 21.75%. Found: C 66.61%; H 6.59%; N 21.98%. ESI + MS; [C $_{32}$ H $_{37}$ N $_9$ O $_2$ +Na $^+$] found: 602.2968.

3.1.1.4.3. *3-[[1-{2-[4-(4-Cyano-1-isobutyl-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl)piperazin-1-yl]-2-oxoethyl]-1H-1,2,3-triazol-4-yl]methoxy]-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (6d).* The reaction between compound **3b** and **5b** produced a white solid in 79% yield; mp 166–168 °C; IR ν/cm^{-1} : 1673 (C=O), 2206, 2217 (C≡N). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 0.94 (d, J = 6.7 Hz, 6H, CH(CH $_3$) $_2$), 1.77–1.88 (m, 4H, 6,7-CH $_2$), 2.07–2.22 (m, 3H, 6'-CH $_2$, CH(CH $_3$) $_2$), 2.45 (s, 3H, CH $_3$), 2.48 (d, J = 7.1 Hz, 2H, CHCH $_2$), 2.57–2.63 (m, 2H, 8-CH $_2$), 2.81–2.88 (m, 4H, 5,7'-CH $_2$), 3.02 (t, J = 7.6 Hz, 2H, 5'-CH $_2$), 3.56–3.74 (m, 8H, C $_4$ H $_8$ N $_2$), 5.47 (s, 2H, OCH $_2$), 5.52 (s, 2H, NCH $_2$), 7.95 (s, 1H, CH $_{\text{triazole}}$). ^{13}C NMR (75 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 20.90,

21.86, 21.97, 22.17, 23.55, 24.63, 27.26, 27.84, 29.37, 32.51, 41.19, 43.95, 44.13, 47.66, 48.22, 50.35, 59.31, 90.24, 92.72, 113.69, 116.03, 123.78, 125.55, 129.45, 141.77, 151.97, 158.08, 158.49, 158.95, 160.15, 160.18, 163.75. Anal. calcd for C $_{33}$ H $_{39}$ N $_9$ O $_2$: C 66.76%; H 6.62%; N 21.23%. Found: C 67.11%; H 6.81%; N 21.48%. ESI + MS; [C $_{33}$ H $_{39}$ N $_9$ O $_2$ +Na $^+$] found: 616.3124.

3.1.1.4.4. *3-{4-[[4-[[[4-Cyano-1-methyl-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]acetyl]piperazin-1-yl]-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (6e).* The reaction between compound **3c** and **5b** produced a white solid in 76% yield; mp 198–200 °C; IR ν/cm^{-1} : 1658 (C=O), 2202, 2219 (C≡N). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.77–1.88 (m, 8H, 6,6',7,7'-CH $_2$), 2.36 (s, 3H, CH $_3$), 2.45 (s, 3H, CH $_3$), 2.53–2.63 (m, 4H, 8,8'-CH $_2$), 2.80–2.89 (m, 4H, 5,5'-CH $_2$), 3.51–3.74 (m, 8H, C $_4$ H $_8$ N $_2$), 5.47 (s, 2H, OCH $_2$), 5.52 (s, 2H, NCH $_2$), 7.96 (s, 1H, CH $_{\text{triazole}}$). ^{13}C NMR (75 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 20.85, 21.10, 21.82, 21.85, 21.89, 21.94, 22.15, 24.59, 24.62, 27.80, 27.92, 41.21, 43.99, 47.77, 48.22, 50.32, 59.28, 92.67, 93.86, 113.65, 115.83, 122.56, 123.74, 125.58, 150.83, 151.93, 158.45, 158.66, 158.79, 160.14, 163.73. Anal. calcd for C $_{31}$ H $_{35}$ N $_9$ O $_2$: C 65.82%; H 6.24%; N 22.29%. Found: C 66.19%; H 6.45%; N 22.56%. ESI + MS; [C $_{31}$ H $_{35}$ N $_9$ O $_2$ +Na $^+$] found: 588.2811.

3.1.1.4.5. *3-[[1-{2-[4-(4-Cyano-1-isopropyl-5,6,7,8-tetrahydroisoquinolin-3-yl)piperazin-1-yl]-2-oxoethyl]-1H-1,2,3-triazol-4-yl]methoxy]-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (6f).* The reaction between compound **3d** and **5b** produced a white solid in 82% yield; mp 119–121 °C; IR ν/cm^{-1} : 1668 (C=O), 2210 (C≡N). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.19 (d, J = 6.6 Hz, 6H, CH(CH $_3$) $_2$), 1.77–1.87 (m, 8H, 6,6',7,7'-CH $_2$), 2.45 (s, 3H, CH $_3$), 2.58–2.69 (m, 4H, 8,8'-CH $_2$), 2.82–2.89 (m, 4H, 5,5'-CH $_2$), 3.17 (sp, J = 6.6 Hz, 1H, CH(CH $_3$) $_2$), 3.55–3.76 (m, 8H, C $_4$ H $_8$ N $_2$), 5.47 (s, 2H, OCH $_2$), 5.52 (s, 2H, NCH $_2$), 7.94 (s, 1H, CH $_{\text{triazole}}$). ^{13}C NMR (75 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 20.87, 20.90, 21.07, 21.83, 21.94, 22.01, 23.81, 24.60, 27.80, 28.22, 30.29, 41.15, 41.19, 43.98, 47.59, 48.20, 50.31, 59.29, 92.70, 93.70, 113.64, 115.84, 121.03, 123.74, 125.54, 141.7, 151.42, 151.93, 158.44, 158.86, 160.16, 163.69, 165.98. Anal. calcd for C $_{33}$ H $_{39}$ N $_9$ O $_2$: C 66.76%; H 6.62%; N 21.23%. Found: C 67.09%; H 6.80%; N 21.47%. ESI + MS; [C $_{33}$ H $_{39}$ N $_9$ O $_2$ +Na $^+$] found: 616.3124.

3.1.1.4.6. *3-[[1-{2-[4-(4-Cyano-1-isobutyl-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl)piperazin-1-yl]-2-oxoethyl]-1H-1,2,3-triazol-4-yl]methoxy]-1-ethyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (6g).* The reaction between compound **3b** and **5c** produced a white solid in 77% yield; mp 140–142 °C; IR ν/cm^{-1} : 1661 (C=O), 2205, 2220 (C≡N). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 0.94 (d, J = 6.6 Hz, 6H, CH(CH $_3$) $_2$), 1.30 (t, J = 7.5 Hz, 3H, CH $_2$ CH $_3$), 1.77–1.88 (m, 4H, 6,7-CH $_2$), 2.08–2.22 (m, 3H, 6'-CH $_2$, CH(CH $_3$) $_2$), 2.48 (d, J = 7.1 Hz, 2H, CHCH $_2$), 2.61–2.67 (m, 2H, 8-CH $_2$), 2.74 (q, J = 7.5 Hz, 2H, CH $_2$ CH $_3$), 2.82–2.89 (m, 4H, 5,7'-CH $_2$), 3.02 (t, J = 7.6 Hz, 2H, 5'-CH $_2$), 3.56–3.75 (m, 8H, C $_4$ H $_8$ N $_2$), 5.47 (s, 2H, OCH $_2$), 5.55 (s, 2H, NCH $_2$), 7.93 (s, 1H, CH $_{\text{triazole}}$). ^{13}C NMR (75 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 11.25, 20.89,



21.87, 22.16, 23.52, 24.00, 27.16, 27.24, 27.92, 29.35, 32.49, 41.16, 43.94, 44.10, 47.64, 48.20, 50.31, 59.23, 90.22, 92.58, 113.70, 115.99, 123.13, 125.30, 129.43, 141.83, 152.05, 158.05, 158.92, 160.13, 160.37, 162.45, 163.70. Anal. calcd for $C_{34}H_{41}N_9O_2$: C 67.19%; H 6.80%; N 20.74%. Found: C 67.58%; H 7.02%; N 21.01%. ESI + MS; $[C_{34}H_{41}N_9O_2^+Na^+]$ found: 630.3281.

3.1.1.4.7. 3-(4-[[4-[[4-Cyano-1-ethyl-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]acetyl]piperazin-1-yl]-1-(2-furyl)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (**6h**). The reaction between compound **3e** and **5c** produced a brown solid in 74% yield; solid; mp 216–218 °C; IR ν/cm^{-1} : 1678 (C=O), 2204, 2215 (C≡N). 1H NMR (300 MHz, DMSO- d_6/CCl_4 , 1/3) δ 1.30 (t, $J = 7.4$ Hz, 3H, CH_2CH_3), 1.77–1.88 (m, 8H, 6,6',7,7'- CH_2), 2.60–2.66 (m, 2H, 8- CH_2), 2.74 (q, $J = 7.4$ Hz, 2H, CH_2CH_3), 2.81–2.87 (m, 2H, 8'- CH_2), 2.88–2.94 (m, 2H, 5- CH_2), 2.94–3.00 (m, 2H, 5'- CH_2), 3.56–3.77 (m, 8H, $C_4H_8N_2$), 5.49 (s, 2H, OCH₂), 5.54 (s, 2H, NCH₂), 6.59 (dd, $J = 3.5, 1.7$ Hz, 1H, 4- CH_{furr}), 7.10 (dd, $J = 3.5, 0.8$ Hz, 1H, 3- CH_{furr}), 7.72 (dd, $J = 1.7, 0.8$ Hz, 1H, 5- CH_{furr}), 7.96 (s, 1H, $CH_{triazole}$). ^{13}C NMR (75 MHz, DMSO/ CCl_4 , 1/3) δ 11.27, 20.83, 21.80, 21.94, 23.93, 25.52, 27.16, 27.93, 28.58, 41.15, 43.86, 47.77, 48.17, 50.40, 59.05, 92.34, 94.68, 111.47, 113.76, 113.96, 115.94, 121.20, 123.41, 125.73, 144.23, 147.22, 152.24, 152.91, 153.30, 158.45, 160.31, 162.64, 163.94. Anal. calcd for $C_{35}H_{37}N_9O_3$: C 66.54%; H 5.90%; N 19.95%. Found: C 66.85%; H 6.06%; N 20.18%. ESI + MS; $[C_{35}H_{37}N_9O_3^+Na^+]$ found: 654.2917.

3.1.1.4.8. 3-[[1-(2-[4-(4-Cyano-1-propyl-6,7-dihydro-5H-cyclopenta[c]pyridin-3-yl)piperazin-1-yl]-2-oxoethyl)-1H-1,2,3-triazol-4-yl]methoxy]-1-isopropyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (**6i**). The reaction between compound **3a** and **5d** produced a white solid in 80% yield; mp 211–213 °C; IR ν/cm^{-1} : 1674 (C=O), 2101, 2218 (C≡N). 1H NMR (300 MHz, DMSO- d_6/CCl_4 , 1/3) δ 0.98 (d, $J = 7.4$ Hz, 3H, CH_2CH_3), 1.25 (d, $J = 6.7$ Hz, 6H, $CH(CH_3)_2$), 1.65–1.78 (m, 2H, CH_2CH_3), 1.78–1.87 (m, 4H, 6,7- CH_2), 2.10–2.21 (m, 2H, 6'- CH_2), 2.56–2.62 (m, 2H, $CH_2C_2H_5$), 2.66–2.72 (m, 2H, 8- CH_2), 2.82–2.90 (m, 4H, 5,7'- CH_2), 3.02 (t, $J = 7.6$ Hz, 2H, 5'- CH_2), 3.22 (sp, $J = 6.7$ Hz, 1H, $CH(CH_3)_2$), 3.57–3.75 (m, 8H, $C_4H_8N_2$), 5.47 (s, 2H, OCH₂), 5.56 (s, 2H, NCH₂), 7.92 (s, 1H, $CH_{triazole}$). ^{13}C NMR (75 MHz, DMSO- d_6/CCl_4 , 1/3) δ 13.50, 20.41, 20.84, 20.89, 20.92, 21.98, 23.52, 23.82, 28.11, 29.14, 30.35, 32.44, 37.06, 41.16, 43.94, 47.63, 48.17, 50.32, 59.20, 90.16, 92.72, 113.68, 116.01, 122.21, 125.09, 128.96, 141.86, 152.51, 158.51, 159.05, 160.12, 160.48, 163.69, 166.02. Anal. calcd for $C_{34}H_{41}N_9O_2$: C 67.19%; H 6.80%; N 20.74%. Found: C 67.59%; H 7.02%; N 21.03%. ESI + MS; $[C_{34}H_{41}N_9O_2^+Na^+]$ found: 630.3281.

3.1.1.4.9. 3-(4-[[4-[[4-Cyano-1-(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]acetyl]piperazin-1-yl]-1-isopropyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (**6k**). The reaction between compound **3d** and **5f** produced a white solid in 87% yield; mp 192–194 °C; IR ν/cm^{-1} : 1684 (C=O), 2199, 2219 (C≡N). 1H NMR (300 MHz, DMSO- d_6/CCl_4 , 1/3) δ 1.18 (d, $J = 6.6$ Hz, 6H, $CH(CH_3)_2$), 1.77–1.87 (m, 8H, 6,6',7,7'- CH_2), 2.61–2.68 (m, 2H, 8- CH_2), 2.82–3.04 (m, 6H,

5,5',8'- CH_2), 3.17 (sp, $J = 6.6$ Hz, 1H, $CH(CH_3)_2$), 3.54–3.74 (m, 8H, $C_4H_8N_2$), 5.45 (s, 2H, OCH₂), 5.59 (s, 2H, NCH₂), 6.62 (dd, $J = 3.5, 1.7$ Hz, 1H, 4- CH_{furr}), 7.25 (dd, $J = 3.5, 0.8$ Hz, 1H, 3- CH_{furr}), 7.73 (dd, $J = 1.7, 0.8$ Hz, 1H, 5- CH_{furr}), 8.01 (s, 1H, $CH_{triazole}$). ^{13}C NMR (75 MHz, DMSO- d_6/CCl_4 , 1/3) δ 20.95, 21.81, 21.90, 23.69, 25.36, 28.11, 28.33, 30.18, 41.05, 43.86, 47.48, 48.07, 50.28, 59.35, 93.48, 93.58, 111.47, 113.49, 114.25, 120.91, 121.96, 125.74, 144.02, 146.39, 151.30, 152.49, 154.01, 158.73, 159.58, 163.54, 165.85. Anal. calcd for $C_{36}H_{39}N_9O_3$: C 66.96%; H 6.09%; N 19.52%. Found: C 67.28%; H 6.26%; N 19.77%. ESI + MS; $[C_{36}H_{39}N_9O_3^+Na^+]$ found: 668.3074.

3.1.1.4.10. 3-(4-[[4-[[4-Cyano-1-(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy]methyl]-1H-1,2,3-triazol-1-yl]acetyl]piperazin-1-yl]-1-(2-furyl)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (**6l**). The reaction between compound **3e** and **5f** produced a light-yellow solid in 78% yield; mp 170–172 °C; IR ν/cm^{-1} : 1671 (C=O), 2204, 2224 (C≡N). 1H NMR (300 MHz, DMSO- d_6/CCl_4 , 1/3) δ 1.79–1.90 (m, 8H, 6,6',7,7'- CH_2), 2.85–3.04 (m, 8H, 8,8',5,5'- CH_2), 3.56–3.76 (m, 8H, $C_4H_8N_2$), 5.47 (s, 2H, OCH₂), 5.60 (s, 2H, NCH₂), 6.57 (dd, $J = 3.5, 1.7$ Hz, 1H, 4- CH_{furr}), 6.62 (dd, $J = 3.5, 1.7$ Hz, 1H, 4'- CH_{furr}), 7.09 (dd, $J = 3.5, 0.8$ Hz, 1H, 3- CH_{furr}), 7.25 (dd, $J = 3.5, 0.7$ Hz, 1H, 3'- CH_{furr}), 7.68 (dd, $J = 1.7, 0.8$ Hz, 1H, 5- CH_{furr}), 7.68 (dd, $J = 1.7, 0.7$ Hz, 1H, 5'- CH_{furr}), 8.02 (s, 1H, $CH_{triazole}$). ^{13}C NMR (75 MHz, DMSO- d_6/CCl_4 , 1/3) δ 20.62, 20.90, 21.93, 22.00, 25.50, 28.45, 28.57, 41.13, 41.17, 43.96, 47.73, 48.18, 50.39, 59.45, 93.61, 94.80, 111.32, 111.59, 113.54, 113.62, 114.38, 115.74, 121.07, 122.10, 125.63, 143.79, 144.16, 146.53, 147.19, 152.60, 153.13, 153.16, 154.15, 158.43, 159.72, 163.75. Anal. calcd for $C_{37}H_{35}N_9O_4$: C 66.35%; H 5.27%; N 18.82%. Found: C 66.65%; H 5.48%; N 19.11%. ESI + MS; $[C_{37}H_{35}N_9O_4^+Na^+]$ found: 692.2710.

3.1.1.4.11. 6-[[1-(2-[4-(5-Cyano-8-ethyl-3,3-dimethyl-3,4-dihydro-1H-pyrano[3,4-c]pyridin-6-yl)piperazin-1-yl]-2-oxoethyl)-1H-1,2,3-triazol-4-yl]methoxy]-8-(4-methoxyphenyl)-3,3-dimethyl-3,4-dihydro-1H-pyrano[3,4-c]pyridine-5-carbonitrile (**6n**). The reaction between compound **3g** and **5h** produced a white solid in 83% yield; mp 128–130 °C; IR ν/cm^{-1} : 1650 (C=O), 2218 (C≡N). 1H NMR (300 MHz, DMSO- d_6/CCl_4 , 1/3) δ 1.24 (t, $J = 7.4$ Hz, 3H, CH_2CH_3), 1.28 (s, 6H, $C(CH_3)_2$), 1.33 (s, 6H, $C(CH_3)_2$), 2.57 (q, $J = 7.4$ Hz, 2H, CH_2CH_3), 2.72 (s, 2H, 4- CH_2), 2.85 (s, 2H, 4'- CH_2), 3.61–3.75 (m, 8H, $C_4H_8N_2$), 3.87 (s, 3H, OCH₃), 4.60 (s, 2H, 1- CH_2), 4.68 (s, 2H, 1'- CH_2), 5.49 (s, 2H, OCH₂), 5.61 (s, 2H, NCH₂), 6.97–7.02 (m, 2H, C_6H_4), 7.52–7.58 (m, 2H, C_6H_4), 7.96 (s, 1H, $CH_{triazole}$). ^{13}C NMR (75 MHz, DMSO- d_6/CCl_4 , 1/3) δ 10.90, 25.76, 26.20, 26.46, 37.87, 38.16, 41.21, 43.97, 47.41, 47.93, 50.38, 54.70, 58.84, 59.59, 59.88, 69.01, 69.19, 93.04, 93.57, 113.32, 113.38, 115.63, 118.79, 121.18, 125.49, 129.62, 130.01, 141.64, 147.87, 150.56, 155.32, 159.15, 159.42, 160.01, 160.75, 163.832. Anal. calcd for $C_{40}H_{45}N_9O_5$: C 65.65%; H 6.20%; N 17.23%. Found: C 66.01%; H 6.39%; N 17.50%. ESI + MS; $[C_{40}H_{45}N_9O_5^+Na^+]$ found: 754.3441.

3.1.1.4.12. 6-[[1-(2-[4-(4-Cyano-1-methyl-5,6,7,8-tetrahydroisoquinolin-3-yl)piperazin-1-yl]-2-oxoethyl)-1H-1,2,3-triazol-4-yl]methoxy]-8-(2-furyl)-3,3-dimethyl-3,4-dihydro-1H-pyrano[3,4-c]pyridine-5-carbonitrile (**6o**). The reaction between compound **3c**



and **5i** produced a brown solid in 75% yield; mp 215–217 °C; IR ν/cm^{-1} : 1667 (C=O), 2205, 2223 (C≡N). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.31 (s, 6H, C(CH $_3$) $_2$), 1.77–1.87 (m, 4H, 6',7'-CH $_2$), 2.36 (s, 3H, CH $_3$), 2.53–2.59 (m, 2H, 8'-CH $_2$), 2.80–2.86 (m, 2H, 5'-CH $_2$), 2.83 (s, 2H, 4-CH $_2$), 3.50–3.73 (m, 8H, C $_4$ H $_8$ N $_2$), 5.00 (s, 2H, 8-CH $_2$), 5.47 (s, 2H, OCH $_2$), 5.63 (s, 2H, NCH $_2$), 6.66 (dd, J = 3.5, 1.7 Hz, 1H, 4-CH $_{\text{fur}}$), 7.36 (dd, J = 3.5, 0.7 Hz, 1H, 3-CH $_{\text{fur}}$), 7.79 (dd, J = 1.7, 0.7 Hz, 1H, 5-CH $_{\text{fur}}$), 8.01 (s, 1H, CH $_{\text{triazole}}$). ^{13}C NMR (75 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 21.14, 21.91, 22.17, 24.65, 25.72, 27.94, 38.33, 41.25, 43.99, 47.76, 47.79, 48.23, 50.39, 59.69, 59.82, 68.46, 93.80, 93.86, 111.97, 113.26, 114.44, 115.85, 119.04, 122.58, 125.59, 141.56, 143.46, 144.91, 150.85, 150.97, 152.42, 158.67, 158.81, 160.32, 163.73. Anal. calcd for C $_{35}$ H $_{37}$ N $_9$ O $_4$: C 64.90%; H 5.76%; N 19.46%. Found: C 65.24%; H 5.93%; N 19.71%. ESI + MS; [C $_{35}$ H $_{37}$ N $_9$ O $_4$ +Na $^+$] found: 670.2866.

3.1.1.4.13. 6-[[1-(2-{4-[4-Cyano-1-(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl]piperazin-1-yl}-2-oxoethyl)-1H-1,2,3-triazol-4-yl]methoxy]-8-(2-furyl)-3,3-dimethyl-3,4-dihydro-1H-pyranol[3,4-*c*]pyridine-5-carbonitrile (**6p**). The reaction between compound **3e** and **5i** produced a white solid in 71% yield; mp 220–222 °C; IR ν/cm^{-1} : 1678 (C=O), 2214 (C≡N). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.31 (s, 6H, C(CH $_3$) $_2$), 1.78–1.90 (m, 4H, 6,7-CH $_2$), 2.82 (s, 2H, 5-CH $_2$), 2.86–3.01 (m, 4H, 8',5'-CH $_2$), 3.56–3.77 (m, 8H, C $_4$ H $_8$ N $_2$), 5.00 (s, 2H, 8-CH $_2$), 5.48 (s, 2H, OCH $_2$), 5.62 (s, 2H, NCH $_2$), 6.57 (dd, J = 3.5, 1.7 Hz, 1H, 4-CH $_{\text{fur}}$), 6.66 (dd, J = 3.5, 1.7 Hz, 1H, 4'-CH $_{\text{fur}}$), 7.08–7.11 (m, 1H, 3-CH $_{\text{fur}}$), 7.34–7.38 (m, 1H, 3'-CH $_{\text{fur}}$), 7.68–7.70 (m, 1H, 5-CH $_{\text{fur}}$), 7.78–7.80 (m, 1H, 5'-CH $_{\text{fur}}$), 8.02 (s, 1H, CH $_{\text{triazole}}$). ^{13}C NMR (75 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 20.81, 21.91, 25.43, 25.64, 28.50, 38.23, 41.11, 43.85, 43.88, 47.67, 48.07, 50.38, 59.61, 59.66, 59.74, 68.38, 93.67, 94.65, 111.28, 111.93, 113.24, 113.52, 114.40, 115.73, 118.94, 120.98, 125.75, 143.35, 143.79, 144.90, 147.08, 150.88, 152.32, 153.07, 158.32, 160.22, 163.70. Anal. calcd for C $_{38}$ H $_{37}$ N $_9$ O $_5$: C 65.22%; H 5.33%; N 18.01%. Found: C 65.61%; H 5.56%; N 18.29%. ESI + MS; [C $_{38}$ H $_{37}$ N $_9$ O $_5$ +Na $^+$] found: 722.2816.

3.1.1.4.14. 6-(4-[[4-[[5-Cyano-8-(2-furyl)-3,3-dimethyl-3,4-dihydro-1H-pyranol[3,4-*c*]pyridin-6-yl]oxy]methyl)-1H-1,2,3-triazol-1-yl]acetyl]piperazin-1-yl)-3,3,8-trimethyl-3,4-dihydro-1H-pyranol[3,4-*c*]pyridine-5-carbonitrile (**6q**). The reaction between compound **3f** and **5i** produced a white solid in 80% yield; mp 243–245 °C; IR ν/cm^{-1} : 1672 (C=O), 2209, 2225 (C≡N). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.28 (s, 6H, C(CH $_3$) $_2$), 1.31 (s, 6H, C(CH $_3$) $_2$), 2.31 (s, 3H, CH $_3$), 2.71 (s, 2H, 5-CH $_2$), 2.83 (s, 2H, 5'-CH $_2$), 3.57–3.75 (m, 8H, C $_4$ H $_8$ N $_2$), 4.57 (s, 2H, 8-CH $_2$), 5.00 (s, 2H, 8'-CH $_2$), 5.48 (s, 2H, OCH $_2$), 5.63 (s, 2H, NCH $_2$), 6.66 (dd, J = 3.5, 1.7 Hz, 1H, 4-CH $_{\text{fur}}$), 7.36 (dd, J = 3.5, 0.7 Hz, 1H, 3-CH $_{\text{fur}}$), 7.80 (dd, J = 1.7, 0.8 Hz, 1H, 5-CH $_{\text{fur}}$), 8.01 (s, 1H, CH $_{\text{triazole}}$). ^{13}C NMR (75 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 21.01, 25.74, 37.74, 41.25, 43.97, 47.48, 47.97, 50.40, 59.20, 59.69, 59.82, 68.47, 69.06, 93.23, 93.80, 111.99, 113.29, 114.46, 115.57, 119.07, 119.43, 125.60, 141.56, 143.48, 144.94, 147.76, 151.00, 152.42, 155.42, 159.09, 160.34, 163.82. Anal. calcd for C $_{36}$ H $_{39}$ N $_9$ O $_5$: C 63.80%; H 5.80%; N 18.60%. Found: C 64.12%; H 5.98%; N 18.84%. ESI + MS; [C $_{36}$ H $_{39}$ N $_9$ O $_5$ +Na $^+$] found: 700.2972.

3.1.1.5. *General procedure for the synthesis of compounds 8a–c*. To compound **7** (5 mmol) in absolute ethanol, phenylisothiocyanate (5 mmol) was added and the mixture was stirred for 5 h at room temperature, and then 5 h at 35–40 °C. After the mixture was cooled, the precipitate was filtered, washed with ethanol, dried and recrystallized from ethanol.

3.1.1.5.1. 2-[[[4-Cyano-1-methyl-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy]acetyl]-*N*-phenylhydrazinecarbothioamide (**8a**). The reaction between compound **7a** and phenylisothiocyanate produced a colorless solid in 83% yield; mp 167–169 °C. ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.78–1.88 (m, 4H, 6,7-CH $_2$), 2.33 (s, 3H, CH $_3$), 2.53–2.60 (m, 2H, 8-CH $_2$), 2.84–2.90 (m, 2H, 5-CH $_2$), 4.96 (s, 2H, OCH $_2$), 7.08–7.15 (m, 1H, Ph), 7.25–7.32 (m, 2H, Ph), 7.45–7.51 (m, 2H, Ph), 9.24–9.87 (m, 2H, 2NH), 10.09 (br, 1H, NH). ^{13}C NMR (75 MHz, DMSO/CCl $_4$, 1/3) δ 20.90, 21.84, 21.88, 21.92, 24.62, 27.88, 63.15, 92.89, 113.79, 124.21, 124.33, 124.37, 127.46, 138.78, 151.91, 158.45, 159.90, 180.42. Anal. calcd for C $_{20}$ H $_{21}$ N $_5$ O $_2$ S: C 60.74%; H 5.35%; N 17.71%. Found: C 61.03%; H 5.53%; N 17.96%.

3.1.1.5.2. 2-[[[4-Cyano-1-(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy]acetyl]-*N*-phenylhydrazinecarbothioamide (**8b**). The reaction between compound **7b** and phenylisothiocyanate produced a colorless solid in 87% yield; mp 192–194 °C. ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.80–1.90 (m, 4H, 6,7-CH $_2$), 2.92–3.04 (m, 4H, 8,5-CH $_2$), 5.02 (s, 2H, OCH $_2$), 6.55 (m, 1H, 4-CH $_{\text{fur}}$), 7.06–7.68 (m, 7H, Ph, 3,5-CH $_{\text{fur}}$), 9.15–9.92 (m, 2H, 2NH), 10.18 (br, 1H, NH). Anal. calcd for C $_{23}$ H $_{21}$ N $_5$ O $_3$ S: C 61.73%; H 4.73%; N 15.65%. Found: C 62.05%; H 4.92%; N 15.94%.

3.1.1.5.3. 2-[[[4-Cyano-8-(2-furyl)-3,3-dimethyl-3,4-dihydro-1H-pyranol[3,4-*c*]pyridin-6-yl]oxy]acetyl]-*N*-phenylhydrazinecarbothioamide (**8c**). The reaction between compound **7c** and phenylisothiocyanate produced a colorless solid in 81% yield; mp 176–178 °C. ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.32 (s, 6H, C(CH $_3$) $_2$), 2.86 (s, 2H, 5-CH $_2$), 4.98 (s, 2H, 8-CH $_2$), 5.04 (s, 2H, OCH $_2$), 6.55–6.60 (m, 1H, 4-CH $_{\text{fur}}$), 7.06–7.72 (m, 7H, Ph, 3,5-CH $_{\text{fur}}$), 9.15–9.96 (m, 2H, 2NH), 10.20 (br, 1H, NH). Anal. calcd for C $_{24}$ H $_{23}$ N $_5$ O $_4$ S: C 60.36%; H 4.85%; N 14.67%. Found: C 60.67%; H 5.05%; N 14.91%.

3.1.1.6. *General procedure for the synthesis of compounds 9a–c*. To a stirred solution of NaOH (10 mmol) in water (30 mL), the corresponding thiosemicarbazide **8** (5 mmol) was added and the mixture was stirred for 5 h at room temperature, and then 5 h at 40–50 °C. After cooling, the mixture was diluted with water and acidified with hydrochloric acid to pH 5–6. The precipitated crystals were filtered, washed with water, dried and recrystallized from ethanol.

3.1.1.6.1. 3-[[[5-Mercapto-4-phenyl-4H-1,2,4-triazol-3-yl]methoxy]-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (**9a**). The reaction between compound **8a** and NaOH solution produced a colorless solid in 86% yield; mp 209–211 °C; IR ν/cm^{-1} : 1700 (C=S), 2226 (C≡N), 3101 (NH). ^1H NMR (300 MHz, DMSO- d_6 /CCl $_4$, 1/3) δ 1.73–1.86 (m, 4H, 6,7-CH $_2$), 2.32 (s, 3H, CH $_3$), 2.52–2.57 (m, 2H, 8-CH $_2$), 2.79–2.84 (m, 2H, 5-CH $_2$), 5.23



(s, 2H, OCH₂), 7.41–7.53 (m, 5H, Ph), 13.88 (s, 1H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.77, 21.72, 21.80, 24.57, 27.81, 57.14, 92.67, 113.17, 124.57, 127.97, 128.64, 128.86, 132.92, 146.88, 152.11, 158.30, 158.91, 168.69. Anal. calcd for C₂₀H₁₉N₅O₂S: C 63.64%; H 5.07%; N 18.55%. Found: C 63.94%; H 5.25%; N 18.78%.

3.1.1.6.2. *1-(2-Furyl)-3-[(5-mercapto-4-phenyl-4H-1,2,4-triazol-3-yl)methoxy]-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (9b)*. The reaction between compound **8b** and NaOH solution produced a light-yellow solid in 91% yield; mp 235–237 °C; IR ν /cm⁻¹: 1700 (C=S), 2229 (C≡N), 3219 (NH). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.77–1.88 (m, 4H, 6,7-CH₂), 2.86–3.00 (m, 4H, 8,5-CH₂), 5.33 (s, 2H, OCH₂), 6.60 (dd, *J* = 3.5, 1.7 Hz, 1H, 4-CH_{fur}), 7.13 (dd, *J* = 3.5, 0.7 Hz, 1H, 3-CH_{fur}), 7.39–7.52 (m, 5H, Ph), 7.71 (dd, *J* = 1.7, 0.7 Hz, 1H, 5-CH_{fur}), 13.88 (s, 1H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.53, 21.83, 25.43, 28.45, 57.33, 93.42, 111.58, 113.12, 114.56, 122.77, 127.93, 128.65, 128.84, 132.92, 144.29, 146.30, 146.90, 152.32, 154.32, 158.51, 168.73. Anal. calcd for C₂₃H₁₉N₅O₂S: C 64.32%; H 4.46%; N 16.31%. Found: C 64.65%; H 4.67%; N 16.54%.

3.1.1.6.3. *8-(2-Furyl)-6-[(5-mercapto-4-phenyl-4H-1,2,4-triazol-3-yl)methoxy]-3,3-dimethyl-3,4-dihydro-1H-pyran[3,4-*c*]pyridine-5-carbonitrile (9c)*. The reaction between compound **8c** and solution of NaOH produced a colorless solid in 83% yield; mp 222–224 °C; IR ν /cm⁻¹: 1700 (C=S), 2220 (C≡N), 3167 (NH). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.29 (s, 6H, C(CH₃)₂), 2.79 (s, 2H, 5-CH₂), 4.95 (s, 2H, 8-CH₂), 5.39 (s, 2H, OCH₂), 6.63 (dd, *J* = 3.5, 1.7 Hz, 1H, 4-CH_{fur}), 7.23 (dd, *J* = 3.5, 0.7 Hz, 1H, 3-CH_{fur}), 7.38–7.50 (m, 5H, Ph), 7.76 (dd, *J* = 1.7, 0.7 Hz, 1H, 5-CH_{fur}), 13.90 (s, 1H, NH). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 25.69, 38.31, 57.42, 59.73, 68.43, 93.57, 111.93, 112.72, 114.61, 119.67, 127.93, 128.64, 128.81, 132.93, 143.20, 145.05, 146.79, 151.10, 152.13, 159.08, 168.78. Anal. calcd for C₂₄H₂₁N₅O₃S: C 62.73%; H 4.61%; N 15.24%. Found: C 63.09%; H 4.83%; N 15.47%.

3.1.1.7. General procedure for the synthesis of compounds 10a–g. To a stirred suspension of compound **9** (5 mmol) and potassium carbonate (1.38 g, 10 mmol) in absolute DMF (30 mL), the corresponding chloride **2** (5.5 mmol) was added and the reaction mixture was maintained at 65–70 °C for 5 h. After cooling, water was added and the resulting crystals were filtered, washed with water, dried and recrystallized from ethanol.

3.1.1.7.1. *3-[[5-[(2-[4-(4-Cyano-1-propyl-6,7-dihydro-5H-cyclopenta[*c*]pyridin-3-yl)piperazin-1-yl]-2-oxoethyl)thio]-4-phenyl-4H-1,2,4-triazol-3-yl]methoxy]-1-methyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (10a)*. The reaction between compound **2a** and **9a** produced a cream solid in 74% yield; mp 164–166 °C; IR ν /cm⁻¹: 1658 (C=O), 2207, 2212 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 0.97 (t, *J* = 7.4 Hz, 3H, CH₂CH₃), 1.64–1.86 (m, 6H, CH₂CH₃, 6,7-CH₂), 2.09–2.20 (m, 2H, 6'-CH₂), 2.34 (s, 3H, CH₃), 2.52–2.61 (m, 4H, 8-CH₂, CH₂C₂H₅), 2.79–2.90 (m, 4H, 5,7'-CH₂), 3.01 (t, *J* = 7.5 Hz, 2H, 5'-CH₂), 3.53–3.76 (m, 8H, C₄H₈N₂), 4.31 (s, 2H, SCH₂), 5.36 (s, 2H, OCH₂), 7.47–7.57 (m, 5H, Ph). ¹³C NMR (75 MHz, DMSO-*d*₆/

CCl₄, 1/3) δ 13.51, 20.39, 20.79, 21.75, 21.81, 23.52, 24.58, 27.80, 29.14, 32.44, 35.93, 37.05, 41.13, 45.06, 47.64, 48.25, 57.04, 90.14, 92.59, 113.33, 116.01, 124.35, 126.98, 128.94, 129.16, 129.45, 132.24, 150.66, 151.47, 152.00, 158.36, 158.49, 159.03, 159.18, 160.10, 164.64. Anal. calcd for C₃₈H₄₁N₉O₂S: C 66.35%; H 6.01%; N 18.33%. Found: C 66.70%; H 6.21%; N 18.63%.

3.1.1.7.2. *6-(4-[[[5-[[[4-Cyano-1-methyl-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy]methyl]-4-phenyl-4H-1,2,4-triazol-3-yl]thio]acetyl]piperazin-1-yl]-3,3,8-trimethyl-3,4-dihydro-1H-pyran[3,4-*c*]pyridine-5-carbonitrile (10b)*. The reaction between compound **2f** and **9a** produced a cream solid in 70% yield; mp 119–121 °C; IR ν /cm⁻¹: 1647 (C=O), 2218 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.27 (s, 6H, C(CH₃)₂), 1.74–1.86 (m, 4H, 6,7-CH₂), 2.30 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 2.52–2.58 (m, 2H, 8-CH₂), 2.71 (s, 2H, 5'-CH₂), 2.78–2.86 (m, 2H, 5-CH₂), 3.54–3.76 (m, 8H, C₄H₈N₂), 4.31 (s, 2H, SCH₂), 4.56 (s, 2H, 8'-CH₂), 5.36 (s, 2H, OCH₂), 7.47–7.57 (m, 5H, Ph). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.78, 20.99, 21.74, 21.82, 24.57, 25.74, 27.80, 35.91, 37.72, 41.18, 45.07, 47.50, 48.01, 57.04, 59.20, 69.05, 92.58, 93.22, 113.35, 115.53, 119.36, 124.37, 126.98, 129.17, 129.45, 132.24, 147.73, 150.69, 151.47, 152.01, 155.37, 158.38, 159.07, 159.18, 164.71. Anal. calcd for C₃₈H₄₁N₉O₃S: C 64.84%; H 5.87%; N 17.91%. Found: C 65.21%; H 6.06%; N 18.19%. ESI + MS; [C₃₈H₄₁N₉O₃S₄H⁺] found: 704.3135.

3.1.1.7.3. *3-[[5-[(2-[4-(4-Cyano-1-propyl-6,7-dihydro-5H-cyclopenta[*c*]pyridin-3-yl)piperazin-1-yl]-2-oxoethyl)thio]-4-phenyl-4H-1,2,4-triazol-3-yl]methoxy]-1-(2-furyl)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (10c)*. The reaction between compound **2a** and **9b** produced a cream solid in 76% yield; mp 160–162 °C; IR ν /cm⁻¹: 1648 (C=O), 2207, 2220 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 0.97 (t, *J* = 7.4 Hz, 3H, CH₂CH₃), 1.64–1.79 (m, 2H, CH₂CH₃), 1.78–1.88 (m, 4H, 6,7-CH₂), 2.09–2.20 (m, 2H, 6'-CH₂), 2.55–2.61 (m, 4H, 8-CH₂, CH₂C₂H₅), 2.81–2.89 (m, 2H, 7'-CH₂), 2.96–3.04 (m, 4H, 5,5'-CH₂), 3.53–3.76 (m, 8H, C₄H₈N₂), 4.31 (s, 2H, SCH₂), 5.47 (s, 2H, OCH₂), 6.60 (dd, *J* = 3.5, 1.7 Hz, 1H, 4-CH_{fur}), 7.21 (dd, *J* = 3.5, 0.7 Hz, 1H, 3-CH_{fur}), 7.45–7.56 (m, 5H, Ph), 7.70 (dd, *J* = 1.7, 0.7 Hz, 1H, 5-CH_{fur}). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 13.51, 20.39, 20.55, 21.86, 23.52, 25.38, 28.43, 29.13, 32.44, 35.94, 37.05, 41.12, 45.03, 47.63, 48.25, 57.28, 90.13, 93.34, 111.56, 113.24, 114.62, 116.01, 122.55, 126.93, 128.92, 129.16, 129.42, 132.24, 144.18, 146.38, 150.69, 151.50, 152.50, 154.20, 158.49, 158.74, 159.02, 160.10, 164.62. Anal. calcd for C₄₁H₄₁N₉O₃S: C 66.56%; H 5.59%; N 17.04%. Found: C 66.87%; H 5.79%; N 17.32%.

3.1.1.7.4. *6-[4-[[[5-[[[4-Cyano-1-(2-furyl)-5,6,7,8-tetrahydroisoquinolin-3-yl]oxy]methyl]-4-phenyl-4H-1,2,4-triazol-3-yl]thio]acetyl]piperazin-1-yl]-3,3,8-trimethyl-3,4-dihydro-1H-pyran[3,4-*c*]pyridine-5-carbonitrile (10d)*. The reaction between compound **2f** and **9b** produced a cream solid in 73% yield; mp 193–195 °C; IR ν /cm⁻¹: 1647 (C=O), 2211, 2219 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.27 (s, 6H, C(CH₃)₂), 1.78–1.87 (m, 4H, 6,7-CH₂), 2.30 (s, 3H, CH₃), 2.70 (s, 2H, 5'-CH₂), 2.86–2.93 (m, 2H, 8-CH₂), 2.96–3.02 (m, 2H, 5-CH₂), 3.53–3.76 (m, 8H, C₄H₈N₂), 4.30 (s, 2H, SCH₂), 4.56 (s, 2H, 8'-CH₂), 5.46 (s, 2H,



OCH₂), 6.60 (dd, $J = 3.5, 1.7$ Hz, 1H, 4-CH_{furr}), 7.20 (dd, $J = 3.5, 0.7$ Hz, 1H, 3-CH_{furr}), 7.45–7.56 (m, 5H, Ph), 7.70 (dd, $J = 1.7, 0.7$ Hz, 1H, 5-CH_{furr}). ¹³C NMR (75 MHz, DMSO/CCl₄, 1/3) δ 20.56, 21.00, 21.87, 25.40, 25.75, 28.45, 35.88, 37.73, 41.20, 45.07, 47.50, 48.01, 57.29, 59.20, 69.06, 93.23, 93.35, 111.59, 113.27, 114.64, 115.53, 119.37, 122.57, 126.95, 129.18, 129.45, 132.25, 144.21, 146.40, 147.74, 150.72, 151.49, 152.50, 154.21, 155.36, 158.74, 159.08, 164.71. Anal. calcd for C₄₁H₄₁N₉O₄S: C 65.15%; H 5.47%; N 16.68%. Found: C 65.48%; H 5.65%; N 16.97%. [C₄₁H₄₁N₉O₄S·H⁺] found: 756.3082.

3.1.1.7.5. 6-[[5-({2-[4-(4-Cyano-1-methyl-5,6,7,8-tetrahydroisquinolin-3-yl)piperazin-1-yl]-2-oxoethyl}thio)-4-phenyl-4H-1,2,4-triazol-3-yl]methoxy]-8-(2-furyl)-3,3-dimethyl-3,4-dihydro-1H-pyran[3,4-c]pyridine-5-carbonitrile (**10e**). The reaction between compound **2b** and **9c** produced a cream solid in 71% yield; mp 154–156 °C; IR ν /cm⁻¹: 1626 (C=O), 2209, 2228 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆) δ 1.24 (s, 6H, C(CH₃)₂), 1.68–1.78 (m, 4H, 6',7'-CH₂), 2.34 (s, 3H, CH₃), 2.50–2.55 (m, 2H, 8'-CH₂), 2.74–2.80 (m, 2H, 5'-CH₂), 2.79 (s, 2H, 5-CH₂), 3.40–3.65 (m, 8H, C₄H₈N₂), 4.33 (s, 2H, SCH₂), 4.91 (s, 2H, 8-CH₂), 5.60 (s, 2H, OCH₂), 6.75 (dd, $J = 3.5, 1.7$ Hz, 1H, 4-CH_{furr}), 7.29 (dd, $J = 3.5, 0.7$ Hz, 1H, 3-CH_{furr}), 7.45–7.48 (m, 5H, Ph), 7.99 (dd, $J = 1.7, 0.7$ Hz, 1H, 5-CH_{furr}). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 21.10, 21.83, 22.55, 24.54, 25.75, 28.06, 36.28, 38.25, 41.36, 45.06, 48.03, 48.34, 57.70, 59.82, 68.93, 93.23, 93.56, 112.51, 113.71, 115.37, 116.65, 119.71, 123.23, 127.04, 129.58, 129.92, 130.60, 132.41, 143.39, 146.36, 151.41, 151.45, 151.55, 151.62, 151.80, 159.04, 159.41, 159.47, 165.30. Anal. calcd for C₄₁H₄₁N₉O₄S: C 65.15%; H 5.47%; N 16.68%. Found: C 65.47%; H 5.33%; N 16.89%.

3.1.1.7.6. 6-[[5-({2-[4-(4-Cyano-1-(2-furyl)-5,6,7,8-tetrahydroisquinolin-3-yl)piperazin-1-yl]-2-oxoethyl}thio)-4-phenyl-4H-1,2,4-triazol-3-yl]methoxy]-8-(2-furyl)-3,3-dimethyl-3,4-dihydro-1H-pyran[3,4-c]pyridine-5-carbonitrile (**10f**). The reaction between compound **2e** and **9c** produced a brown solid in 79% yield; mp 250–252 °C; IR ν /cm⁻¹: 1649 (C=O), 2216 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.29 (s, 6H, C(CH₃)₂), 1.77–1.90 (m, 4H, 6',7'-CH₂), 2.78 (s, 2H, 5-CH₂), 2.93–3.01 (m, 4H, 5',8'-CH₂), 3.52–3.79 (m, 8H, C₄H₈N₂), 4.31 (s, 2H, SCH₂), 4.95 (s, 2H, 8-CH₂), 5.52 (s, 2H, OCH₂), 6.56 (dd, $J = 3.5, 1.7$ Hz, 1H, 4'-CH_{furr}), 6.63 (dd, $J = 3.5, 1.7$ Hz, 1H, 4-CH_{furr}), 7.08 (dd, $J = 3.5, 0.7$ Hz, 1H, 3'-CH_{furr}), 7.30 (dd, $J = 3.5, 0.7$ Hz, 1H, 3-CH_{furr}), 7.46–7.55 (m, 5H, Ph), 7.67 (dd, $J = 1.7, 0.7$ Hz, 1H, 5'-CH_{furr}), 7.75 (dd, $J = 1.7, 0.7$ Hz, 1H, 5-CH_{furr}). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.90, 22.00, 25.49, 25.68, 28.57, 35.93, 38.29, 41.12, 41.13, 45.04, 47.73, 48.25, 57.43, 59.73, 68.41, 93.46, 94.75, 111.32, 111.93, 112.88, 113.53, 114.73, 115.73, 119.45, 121.01, 126.94, 129.18, 129.43, 132.25, 143.27, 143.76, 145.00, 147.14, 150.66, 150.99, 151.55, 152.24, 153.13, 153.21, 158.38, 159.30, 164.65. Anal. calcd for C₄₄H₄₁N₉O₅S: C 65.41%; H 5.12%; N 15.60%. Found: C 65.53%; H 5.31%; N 15.88%.

3.1.1.7.7. 6-[4-({5-({5-Cyano-8-(2-furyl)-3,3-dimethyl-3,4-dihydro-1H-pyran[3,4-c]pyridin-6-yl}oxy)methyl)-4-phenyl-4H-1,2,4-triazol-3-yl]thio]acetyl]piperazin-1-yl]-3,3,8-trimethyl-3,4-dihydro-1H-pyran[3,4-c]pyridine-5-carbonitrile (**10g**). The

reaction between compound **2f** and **9c** produced a yellow solid in 73% yield; mp 168–170 °C; IR ν /cm⁻¹: 1646 (C=O), 2220 (C≡N). ¹H NMR (300 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 1.27 (s, 6H, C(CH₃)₂), 1.30 (s, 6H, C(CH₃)₂), 2.30 (s, 3H, CH₃), 2.70 (s, 2H, 5'-CH₂), 2.79 (s, 2H, 5-CH₂), 3.54–3.77 (m, 8H, C₄H₈N₂), 4.30 (s, 2H, SCH₂), 4.56 (s, 2H, 8'-CH₂), 4.96 (s, 2H, 8-CH₂), 5.52 (s, 2H, OCH₂), 6.63 (dd, $J = 3.5, 1.7$ Hz, 1H, 4-CH_{furr}), 7.31 (dd, $J = 3.5, 0.7$ Hz, 1H, 3-CH_{furr}), 7.45–7.56 (m, 5H, Ph), 7.75 (dd, $J = 1.7, 0.7$ Hz, 1H, 5-CH_{furr}). ¹³C NMR (75 MHz, DMSO-*d*₆/CCl₄, 1/3) δ 20.99, 25.69, 25.74, 35.89, 37.72, 38.30, 41.19, 45.09, 47.48, 48.01, 57.45, 59.20, 59.74, 68.41, 69.05, 93.22, 93.49, 111.94, 112.86, 114.73, 115.53, 119.34, 119.47, 126.95, 129.18, 129.43, 132.25, 143.28, 144.96, 147.74, 150.66, 151.00, 151.55, 152.27, 155.35, 159.05, 159.31, 164.68. Anal. calcd for C₄₂H₄₃N₉O₅S: C 64.19%; H 5.51%; N 16.04%. Found: C 64.54%; H 5.69%; N 16.31%. [C₄₂H₄₃N₉O₅S⁺H⁺] found: 786.3183.

3.2. Biological evaluation

All new 24 compounds were studied for their possible neurotropic activities as well as side effects on 550 outbred mice weighing 18–24 g and 75 male rats of the Wistar line weighing 120–140 g. As reference compounds, the known antiepileptic drugs ethosuximide and tranquilizer diazepam and nootropic drug piracetam⁵⁷ were used. The psychotropic properties of the substances were investigated at a dose of 50 mg kg⁻¹, given that the ED₅₀ of these compounds were within 50 mg kg⁻¹ at the confidence intervals. The doses of the reference compounds were chosen based on the literature and our experimental data including ethosuximide – 200 mg kg⁻¹, diazepam – 2 mg kg⁻¹ and piracetam – 1000 mg kg⁻¹.^{57,58}

To determine the 50% effective dose (ED₅₀, causing the anticonvulsant effect of 50% of animals, which is calculated by the antagonism to PTZ test), 50% toxic doses (TD₅₀, causing a myorelaxant effect in 50% of animals) and lethal effect in 50% of animals (LD₅₀), the statistical method of probit analysis by Litchfield and Wilcoxon was used.⁵⁹ The acute toxicity was determined by calculating the number of dead animals after 24 h of exposure to doses of 400–1200 mg kg⁻¹. In all the experiments, the results were statistically tested at a $P \leq 0.05$ probability level.

The biological experiments were carried out in full compliance with the European Convention for the Protection of Vertebrate. All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of (ETS No 123, Strasbourg, 03/18/1986): Strasbourg (France).

3.2.1. Evaluation of the anticonvulsant activity of the synthesized compounds. The anticonvulsant effect of the newly synthesized compounds was investigated by pentylenetetrazole (PTZ) and thiosemicarbazide (TSC)-induced convulsion and maximal electroshock (MES) tests.^{33–38} In the case of convulsions induced by PTZ, PTZ was injected subcutaneously at 80 mg kg⁻¹, which induced convulsions in 95% of the animals. Clonic convulsions were recorded. Substances were administered intraperitoneally (i.p.) at doses of 10–200 mg kg⁻¹ a suspension with carboxymethylcellulose with Twin-80 45 min



before the administration of PTZ, TSC and applying electrical stimulation. In all experiments, the solvents were used in the following ratio: a drop of Tween-80 was used to dissolve the substances until smooth, and then carboxymethylcellulose added in the appropriate amount. The control animals were administered an emulsifier. Each dose of each test compound was studied in six animals.

The MES test was used as an animal model for the generalized tonic seizures of epilepsy with the following parameters: 50 mA, duration of 0.2 s, and oscillation frequency of 50 imp per s. The anticonvulsant properties of the compounds was assessed by the prevention of the tonic-extensor phase of convulsions.

Thiosemicarbazide was administered subcutaneously to the mice at a dose of 18 mg kg⁻¹ as a 0.5% solution and caused clonic convulsions in the animals. Anti-thiosemicarbazide activity was evaluated based on the latency time for the onset of seizures.

3.2.2. Evaluation of the psychotropic properties of the synthesized compounds. The psychotropic properties of selected compounds were studied using the “open field”,^{42,43} “elevated plus maze” (EPM),^{44,45} “forced swim”,⁴⁶ and “test for learning and memory” tests.⁴⁷

The exploratory-motor behavior of rats weighing 120–140 g was studied using a modification of the “open field” model. Therefore, an installation featuring a bottom divided into squares with holes (cells) was utilized. The experiments were carried out in the daytime under natural light. During the 5 min experiment, we assessed indicators of activating and sedative behavior, including standing, the number of horizontal and vertical movements, and sniffing the cells. Each compound, control, and comparison analogues in this model had 6 animals. The most effective dose for administering the test compound to rats was determined to be 50 mg kg⁻¹, which was given intraperitoneally.

Anti-anxiety, antidepressant, and sedative effects were studied using the “elevated plus maze” model in mice developed by S. Pellow co-authors (1986). Typically, normal animals display a preference for spending the majority of their time in the closed arms of the maze. The anxiolytic effect of a drug is evaluated by an increase in the number of entries into the open sleeves and the time spent in them, without an increase in general motor activity. The duration spent in the closed arms and the number of attempts to enter the center of the installation are also recorded. In the above-mentioned model, the test compounds and comparison drugs were administered intraperitoneally prior to the experiments. The control animals were administered an emulsifier. The results were processed statistically ($P \leq 0.05$).

The “forced swim” model was used to assess “despair and depression”. The experimental animals were required to swim in a glass container (height of 22 cm and diameter of 14 cm) filled 1/3 of the way with water. Initially, the intact mice displayed vigorous swimming activity, but eventually, they were forced to immobilize. The latency period of immobilization and the total duration of active swimming immobilization were fixed for 6 min.

Test for learning and memory. The anti-amnesic properties of the compounds were studied on the model of electroshock amnesia according to the method reported by Y. Buresh *et al.* with modification.⁴⁷ In rats, a conditioned passive avoidance reaction (CRPA) of a dark–light setting was developed, while the time for training of the animals with CRPA was recorded. An increase in the time spent by the rats in the light compartment compared to the control on the second day indicates the presence of anti-amnesic properties of the compounds.

3.2.3. Evaluation of coordination of movement in the rotating rod test. The potential neurotoxic effects of the substances were also studied. Myorelaxation was assessed using the “rotating rod” test in mice.^{33,48} In this test, the mice were positioned on a metal rod with a corrugated rubber coating, which rotated at a speed of 5 rpm. The number of animals unable to remain on the rod for 2 min was recorded. The compounds, as administered by intraperitoneal injection in doses in the range of 400–800 mg kg⁻¹, were investigated.

3.3. Docking studies

Docking studies were performed using AutoDock 4 (ver. 4.2.6) in the 3D structures of the GABA_A receptor (PDB code: 4COF), SERT (PDB code: 3F3A) and 5-HT_{1A} receptor (PDB code: 3NYA), retrieved from the Protein Data Bank (PDB). For the final preparation of both ligands and protein preparation, the Wizard of AutoDock tools 1.5.6 were used, as previously reported.¹⁷

4. Conclusions

In summary, new 1,2,3- and 1,2,4-triazole-based hybrids (besides compounds **6a**, **j**, and **m**) were synthesized and evaluated for their anticonvulsant activity together with some psychotropic properties. The evaluation revealed that 14 out of the 24 synthesized compounds appeared to be potent anticonvulsants, showing antagonism to pentylenetetrazole and being superior to ethosuximide, but inferior to diazepam. Moreover, the compounds showed low toxicity with acute daily toxicity and greater therapeutic indexes (TI) than that of ethosuximide. In this test, the most active compound was found to be **6n**, which contains two pyrano[3,4-*c*]pyridine rings with an ethyl and *p*-MeOC₆H₄ groups in its structure.

Alternatively, in the TSC model, all the compounds increased the latency of thiosemicarbazide seizures in the same manner as ethosuximide, suggesting a GABAergic mechanism of action.

The evaluation of psychotropic activity revealed activating behavior and high anxiolytic effects for compounds **6b**, **n** and **p**. A higher active swimming time and latent period of first immobilization for compounds **6b**, **c**, **j**, **n** and **q** was observed, indicating their high antidepressant effect.

In the model of electroshock retrograde amnesia, the conditioned response of passive avoidance (CRPA), some compounds increased the time of reproduction of the reflex in the animals. Docking to the GABA_A receptor, which is known as a mechanism of anticonvulsant and anxiolytic activities, as well as to SERT and 5-HT_{1A} receptor, known as a possible



mechanism of antidepressant activity, was performed. The data from the pharmacological studies were completely consistent with the data from the docking analysis. The most active compound **6n** in terms of anticonvulsant and anxiolytic activity shows the greatest affinity for the GABAA receptor. Compounds **6b**, **c**, **j**, **n** and **q**, and especially **6q**, which exhibited a pronounced antidepressant effect, inhibited SERT and the 5-HT1a receptor.

Thus, in general, it can be stated that the 1,2,3-triazole-linked hybrids synthesized based on the pyrano[3,4-*c*]pyridine cycle are the more active compounds. In contrast, the 1,2,4-triazole-linked hybrids showed low activity.

Ethical statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Yerevan State Medical University (YSMU, Yerevan, Armenia) (protocol code 5 and date of approval 24.03.2016), followed the "Principles of laboratory animal care" and carried out in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC).

Data availability

The data supporting this article have been included as part of the ESI.†

Author contributions

Conceptualization, S. N. S., E. K. H., H. A. Y., H. V. J. and A. A. H. performed experiments on the synthesis of all compounds and analyzed the results. R. G. P. and T. A. A. performed the neurotropic activity experiments. A. G. and A. P. performed docking studies. L. Z. recorded the MS spectra. S. N. S., D. S., V. K. and E. G. P. reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

The work was supported by the Science Committee of RA, in the frames of the research project No. 24WS-1D019.

References

- 1 A. Golyala and P. Kwan, *Seizure*, 2017, **44**, 147–156.
- 2 J. Gierbolini, M. Giarratano and S. R. Benbadis, *Expert Opin. Pharmacother.*, 2016, **17**, 885–888.
- 3 R. S. Fisher, C. Acevedo, A. Arzimanoglou, A. Bogacz, J. H. Cross, C. E. Elger, J. Engel, L. Forsgren and J. A. French, *Epilepsia*, 2014, **55**, 475–482.
- 4 K. V. Voronkova, G. S. Golosnaya, I. D. Lemeshko and A. S. Petrukhin, *Epilepsy Paroxysmal Conditions*, 2017, **9**, 79–85.
- 5 O. I. Abdel Salam, M. A. Al-Omar, N. M. Khalifa, A.-G. Amr and M. M. Abdallah, *Z. Naturforsch., C: J. Biosci.*, 2013, **68**, 264–268.
- 6 S. Wang, H. Liu, X. Wang, K. Lei, G. Li, X. Li, L. Wei and Z. Quan, *Arch. Pharm.*, 2019, **352**, 1900106.
- 7 G. Prasanthi, K. V. Prasad and K. Bharathi, *Eur. J. Med. Chem.*, 2013, **66**, 516–525.
- 8 G. Nkombi, G. Terre'Blanche, H. D. Janse van Rensburg and L. J. Legoabe, *Med. Chem. Res.*, 2022, **31**, 1277–1297.
- 9 W. Cheng-Xi, B. Ming and G. Guo-Hua, *Molecules*, 2015, **20**, 20741–20776.
- 10 M. Strzelecka and P. Świątek, *Pharmaceuticals*, 2021, **14**, 224.
- 11 E. Stingaci, M. Zveaghinteva, S. Pogrebnoi, L. Lupascu, V. Valica, L. Uncu, A. Smetanscaia, M. Drumea, A. Petrou, A. Ciric, J. Glamoclija, M. Sokovic, V. Kravtsev, A. Geronikaki and F. Macaev, *Bioorg. Med. Chem. Lett.*, 2020, **30**, 127368.
- 12 S. Dawbaa, D. Nuha, A. E. Evren, M. Y. Cankiliç, L. Yurtta and G. Turan, *J. Mol. Struct.*, 2023, **1282**, 135213.
- 13 D. Kumudha, T. Kalavathi and B. A. Viswanath, *World J. Pharm. Res.*, 2018, **7**, 1614–1619.
- 14 M. Song, W. Zhao, Y. Zhu, W. Liu, X. Deng and Y. Huang, *Front. Chem.*, 2022, **10**, 925281.
- 15 M. X. Song and X. Q. Deng, *J. Enzyme Inhib. Med. Chem.*, 2018, **33**, 453–478.
- 16 S. N. Sirakanyan, T. V. Ghochikyan, D. Spinelli, A. S. Galstyan, A. Geronikaki, M. A. Samvelyan, E. K. Hakobyan and A. A. Hovakimyan, *Arkivoc*, 2022, 7–21.
- 17 S. N. Sirakanyan, D. Spinelli, A. Petrou, A. Geronikaki, V. G. Kartsev, E. K. Hakobyan, H. A. Yegoryan, L. Zuppiroli, R. Zuppiroli, A. G. Ayvazyan, R. G. Paronikyan, T. A. Arakelyan and A. A. Hovakimyan, *Molecules*, 2023, **28**, 921.
- 18 D. B. Ramachary, A. B. Shashank and S. Karthik, *Angew. Chem., Int. Ed.*, 2014, **53**, 10420–10424.
- 19 Zh.-J. Quan, Q. Xu, Zh. Zhang, Y.-X. Da and X.-C. Wang, *Tetrahedron*, 2013, **69**, 881–887.
- 20 N. Seus, M. T. Saraiva, E. E. Alberto, L. Savegnago and D. Alves, *Tetrahedron*, 2012, **68**, 10419–10425.
- 21 S. N. Sirakanyan, M. Hrubša, D. Spinelli, P. Dias, V. Kartsev, A. Carazo, A. A. Hovakimyan, J. Pourová, E. K. Hakobyan, J. Karličková, Sh. Parvin, J. Fadraersada, K. Macáková, A. Geronikaki and P. Mladěnka, *J. Pharm. Pharmacol.*, 2022, **74**, 887–895.
- 22 S. N. Sirakanyan, E. K. Akopyan, R. G. Paronikyan, I. M. Nazaryan, A. G. Akopyan and A. A. Ovakimyan, *Pharm. Chem. J.*, 2019, **53**, 495–499.
- 23 S. N. Sirakanyan, A. S. Noravyan, I. A. Dzhagatspanyan, I. M. Nazaryan, A. A. Ovakimyan, A. G. Akopyan and N. G. Avetisyan, *Pharm. Chem. J.*, 2013, **46**, 591–594.
- 24 S. N. Sirakanyan, V. G. Kartsev, D. Spinelli, A. Geronikaki, A. Petrou, M. Ivanov, J. Glamoclija, M. Sokovic, E. Hakobyan and A. A. Hovakimyan, *Arch. Pharm.*, 2021, **354**, 2000208.



Paper

- 25 L. Gonnet, M. Baron and M. Baltas, *Molecules*, 2021, **26**, 5667.
- 26 D. Pereira, M. Pinto, M. Correia-da-Silva and H. Cidade, *Molecules*, 2022, **27**, 230.
- 27 S. G. Agalave, S. R. Maujan and V. S. Pore, *Chem.-Asian J.*, 2011, **6**, 2696–2718.
- 28 G. V. Lavrenova and V. D. Onipko, *Encyclopedia of Traditional Medicine*, Neva, 2003, pp. 88–90.
- 29 J. F. Lassen, N. R. Holm, G. Stankovic, T. Lefevre, A. Chieffo, D. Hildick-Smith, M. Pan, O. Darremont, R. Albiero and M. Ferenc, *EuroIntervention*, 2014, **10**, 545–560.
- 30 M. E. A. Mekky and M. H. Sanad, *Synth. Commun.*, 2019, **49**, 1385–1395.
- 31 S. N. Sirakanyan, D. Spinelli, A. Geronikaki, A. A. Hovakimyan and A. S. Noravyan, *Tetrahedron*, 2015, **71**, 3263–3272.
- 32 S. N. Sirakanyan, E. K. Hakobyan and A. A. Hovakimyan, *Russ. J. Org. Chem.*, 2018, **54**, 929–932.
- 33 B. Katzung, *Drugs Used in Generalized Seizures, Basic and Clinical Pharmacology, Large Medical Books*, McGraw-Hill, 9th edn, 2003.
- 34 H. G. Vogel and W. H. Vogel, Psychotropic and neurotropic activity, in *Drug Discovery and Evaluation: Pharmacological Assays*, ed. Vogel, H. E., Springer, Berlin & N.-Y., 2008, pp. 569–874.
- 35 W. Löscher and D. Schmidt, *Epilepsy Res.*, 1988, **2**, 145–181.
- 36 E. A. Swinyard, *Experimental Models of Epilepsy*, ed. Purpura D. P., Penry J. K., Tower D., Woodbury D. M. and Walter R., Raven Press, New-York, 1992, pp. 433–458.
- 37 E. Yuen and I. Troconiz, *Seizure*, 2015, **24**, 21–27.
- 38 M. Bialera and H. S. White, *Nat. Rev. Drug Discovery*, 2010, **9**, 68–82.
- 39 W. Löscher, C. Fassbender and B. Nolting, *Epilepsy Res.*, 1991, **8**, 79–94.
- 40 W. Löscher, *Seizure*, 2011, **20**, 359–368.
- 41 M. D. Mashkovsky, *Medicines*, New wave, 16th edn, 2021, p. 1216s.
- 42 S. E. File, *Behav. Brain Res.*, 2001, **125**, 151–157.
- 43 L. Prut and C. Belzung, *Eur. J. Pharmacol.*, 2003, **463**, 3–33.
- 44 S. Pellow, P. Chopin, S. E. File and M. Briley, *J. Neurosci. Methods*, 1985, **14**, 149–167.
- 45 F. G. Graeff, C. F. Netto and Jr. H. Zangrossi, *Neurosci. Biobehav. Rev.*, 1998, **23**, 237–246.
- 46 R. D. Porsolt, G. Anton, N. Blavet and M. Jalfre, *Eur. J. Pharmacol.*, 1978, **47**, 379–391.
- 47 Y. Buresh, O. Bureshova and D. P. Houston, *Methods and Basic Experiments for Investigation of the Brain and Behavior* [in Russian], Moscow, 1991, pp. 175–189.
- 48 M. A. Rogawski and W. Löscher, *Nat. Rev. Neurosci.*, 2004, **5**, 553–564.
- 49 M. Kammerer, M. P. Rassner, T. M. Freiman and T. J. Feuerstein, *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 2011, **384**, 47–57.
- 50 P. S. Miller and A. R. Aricescu, *Nature*, 2014, **512**, 270–275.
- 51 M. H. Saier Jr, *Microbiol. Mol. Biol. Rev.*, 2000, **64**, 354–411.
- 52 R. Perrone, F. Berardi, N. A. Colabufo, E. Lacivita and C. Larizza, *J. Pharm. Pharmacol.*, 2005, **57**, 1319–1327.
- 53 P. Blier, *J. Clin. Psychiatry*, 2001, **62**, 12–17.
- 54 S. K. Singh, C. L. Piscitelli and A. Yamashita, *eScience*, 2008, **322**, 1655–1661.
- 55 W. Kuipers, R. Link, P. J. Standaar, A. R. Stoit, I. Van Wijngaarden, R. Leurs and A. P. Ijzerman, *Mol. Pharmacol.*, 1997, **51**, 889–896.
- 56 D. Wacker, G. Fenalti, M. A. Brown, V. Katritch, R. Abagyan, V. Cherezov and R. C. Stevens, *J. Am. Chem. Soc.*, 2010, **132**, 11443–11445.
- 57 B. Winbla, Piracetam: A Review of Pharmacological Properties and Clinical Uses, *CNS Drug Rev.*, 2005, **11**, 169–182.
- 58 M. D. Mashkovsky, *Lekarstvennyye Sredstvas [Medicines]*, Novaya Volna, Moscow, Russia, 16th edn, 2021, p. 1216.
- 59 T. Litchfield and F. Wilcoxon, *J. Pharmacol. Exp. Ther.*, 1949, **96**, 99–113.

